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ABSTRACT: Purines and related heterocycles substituted at C-2 with 4′-sulfamoylanilino and at C-6 with a variety of groups
have been synthesized with the aim of achieving selectivity of binding to CDK2 over CDK1. 6-Substituents that favor competitive
inhibition at the ATP binding site of CDK2 were identified and typically exhibited 10−80-fold greater inhibition of CDK2
compared to CDK1. Most impressive was 4-((6-([1,1′-biphenyl]-3-yl)-9H-purin-2-yl)amino) benzenesulfonamide (73) that
exhibited high potency toward CDK2 (IC50 0.044 μM) but was ∼2000-fold less active toward CDK1 (IC50 86 μM). This
compound is therefore a useful tool for studies of cell cycle regulation. Crystal structures of inhibitor−kinase complexes showed
that the inhibitor stabilizes a glycine-rich loop conformation that shapes the ATP ribose binding pocket and that is preferred in
CDK2 but has not been observed in CDK1. This aspect of the active site may be exploited for the design of inhibitors that
distinguish between CDK1 and CDK2.
■ INTRODUCTION
The cyclin-dependent kinase (CDK) family of serine/threonine
kinases plays an integral role in the regulation of the eukaryotic
cell cycle as well as having key functions in apoptosis,
transcription, differentiation, and neuronal function.1,2 Dereg-
ulation of the cell cycle, a hallmark of human cancer, is
frequently associated with aberrant CDK activity through
mechanisms that may include mutation/overexpression of
CDKs or mutations to genes encoding proteins that directly
or indirectly modulate CDK activity.3−5 CDK2 activation
entails association with partner cyclins A and E, whereas the
endogenous proteins p21Cip1 and p27Kip1 are inhibitory. Cyclin
E overexpression and/or p27Kip1 suppression are a common
feature of many human tumors.6,7
Pharmacological inhibition of CDK family members is a
potential therapeutic approach for the treatment of cancer. In
this context, a large number of ATP-competitive inhibitors have
been evaluated.5−9 The clinical development of CDK inhibitors
as antitumor agents was originally hampered by poor kinase
selectivity, particularly within the CDK family, and uncertainty
as to which CDK constitutes the most appropriate therapeutic
target.3 However, an appreciation of the roles played by specific
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CDKs in sustaining signaling through dysregulated pathways
that drive particular cancers is leading to more stringent patient
selection and correspondingly improved efficacy. For example,
the highly selective CDK4/6 inhibitor palbociclib has been
approved for the treatment of ER-positive, HER2-negative
breast cancer, while abemaciclib, palbociclib, and ribociclib are
in phase III clinical trials to treat advanced breast cancer in
which signaling through the CDK4/6-retinoblastoma axis is
critical.10 Similarly, agents that target a subset of CDKs are
being evaluated in a range of other clinically defined
segments.11
The validity of CDK2 as a cancer therapeutic target was
originally called into question both by CDK2 knockdown
experiments in which loss of CDK2 failed to induce cell cycle
arrest in a number of tumor cell lines12 and by mouse knockout
experiments where the animals were viable.13,14 However,
applying the rationale outlined above, CDK2 inhibitors are also
expected to have utility in settings in which the cancer is
addicted to enhanced CDK2 activity or where synthetic
lethalities can be identified. Recent studies employing a
chemical genetic approach in which CDK2 expression was
maintained, but kinase activity was inhibited, provides
compelling evidence that CDK2 is a valid cancer target. In a
panel of human cancer cells transformed with various
oncogenes, highly selective small-molecule CDK2 inhibition
resulted in marked growth inhibition.15 CDK2-selective
inhibitors may also have applications in combination therapies
in appropriate clinical settings. For example, a recent study
demonstrated that a combination of phosphatidylinositol-3-
kinase and CDK2 inhibitors induced apoptosis in malignant
glioma xenografts via a synthetic−lethal interaction.16 Accu-
mulating evidence also implicates CDK2 as a prospective
therapeutic target in BRCA-deficient cancers,17 neuroblasto-
ma,18 and ovarian cancer.19 These observations, taken together
with supportive clinical data,20 have led to a resurgence of
interest in CDK2 inhibitors as cancer therapeutic agents.21,22
Ideally, such an inhibitor would discriminate between CDK2
and CDK1 to avoid cell toxicity as a result of inhibiting CDK1,
which is an essential member of the CDK family.
Our previous studies employing a structure-lead approach
resulted in the development of selective ATP-competitive
CDK2 inhibitors based on 2-amino-6-alkoxy- (1; NU2058) and
2-arylamino-6-alkoxy- (2) purine derivatives.23,24 These efforts
were rewarded by the identification of potent purine-based
inhibitors, exemplified by 6-cyclohexylmethoxy-2-(4′-
sulfamoylanilino)purine (3; NU6102, CDK2 IC50 = 5.0
nM)25 as well as alkoxypyrimidine inhibitors (e.g., 4, CDK2
IC50 = 0.8 nM).
26 Importantly, 3 exhibits selectivity for CDK2
over other CDK-family members, proving some 50-fold
selective for CDK2 over CDK1 (IC50 = 250 nM), a kinase
with close structural homology to CDK2. In addition, 3 is only
weakly active against CDK7 and CDK9 (IC50 = 4.4 and 1.1 μM,
respectively). These CDKs play a key role in transcriptional
regulation through phosphorylation of RNA polymerase II.2,27
Modulation of protein synthesis by off-target inhibition of
CDK7/CDK9 has obfuscated previous studies to elucidate the
pharmacological effects of clinically evaluated compounds
initially identified as selective CDK2 inhibitors such as seliciclib
(5), dinaciclib (6), and SNS-032 (7).3,28,29
Crystal structures of purines 1−3 in complex with T160-
phosphorylated CDK2-cyclin A (CDK2-cyclin A) provided
valuable details of inhibitor interactions within the ATP-binding
site.23,24 The purine heterocycle anchored the inhibitor through
a triplet of hydrogen bonds between N-9, N-3, and the 2-amino
group, and the backbone carbonyl moiety of Glu81 and amide
and carbonyl moieties of Leu83, respectively, located in the
hinge region of the kinase (Figure 2). The greater potency and
selectivity of 3 compared with 2 and the parent 2-amino-6-
cyclohexylmethoxypurine 1, has been attributed, at least in part,
to additional interactions of the 2-sulfanilyl substituent of 3
with the specificity surface of CDK2.24,30 Notably, two
hydrogen bond interactions between the sulfonamide group
of 3 and Asp86 facilitate optimal hydrophobic packing of the
arylamino ring.
Extensive structure−activity relationship studies (SARs) at
the purine 2-position of 3 have further established the
importance of these inhibitor−kinase interactions.25 By
contrast, although the 6-cyclohexylmethyl group of 3 occupies
the ribose-binding pocket, the precise nature of the interactions
made by substituents at the purine 6-position with the CDK2
active site remains uncertain, notwithstanding that a large
number of derivatives have previously been evaluated
empirically.31
In this paper, we report the results of studies to characterize
interactions between substituents at the purine 6-position and
the CDK2 ATP-binding site. The effect upon biological activity
of modifying the core purine heterocycle of 3 is also reported.
These studies have resulted in the identification of 4-((6-([1,1′-
biphenyl]-3-yl)-9H-purin-2-yl)amino) benzenesulfonamide 73
as a potent and selective CDK2 inhibitor (IC50 = 44 nM),
exhibiting some 2000-fold-selectivity over CDK1 (IC50 = 86
μM).
■ CHEMISTRY
With a view to establishing the overall contribution of the 6-
cyclohexylmethoxy substituent of 1 and 3 to inhibitor binding,
the simple 6-unsubstituted purines 8, 12, and 13 were required.
2-Aminopurine (8) was commercially available, while the 2-
phenylaminopurine (12) and 2-sulfanilylpurine (13) derivatives
were synthesized as outlined in Scheme 1. Thus, selective
reductive dehalogenation of 6-chloro-2-fluoropurine (10),
prepared from 2-amino-6-chloropurine (9) following a
literature procedure,32 afforded 2-fluoropurine (11). Treatment
of 11 with aniline or 4-aminobenzenesulfonamide (sulfanila-
mide) in 2,2,2-trifluoroethanol (TFE) with catalysis by
trifluoroacetic acid (TFA) as described previously33 gave the
respective 2-arylaminopurines 12 and 13 in good yield. The
required 2-arylaminoguanine derivatives 15 and 16 were also
readily accessible from commercially available 2-bromohypox-
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anthine (14) under similar conditions. The 6-alkoxypurine
derivatives (30−35) were synthesized by utilizing previously
optimized methodology.23,25,31 Briefly, introduction of the 6-
alkoxy substituent was achieved either by direct reaction of the
appropriate sodium alkoxide with 2-amino-6-chloropurine (9)
by employing the corresponding alcohol as solvent or, where
necessary, following conversion into the “DABCO-purine”
intermediate (17).34 Elaboration of the 6-alkoxy-2-amino-
purines (18−23) into the corresponding 2-fluoropurines
(24−29) under Balz−Schiemann conditions enabled subse-
quent introduction of the 2-(4-aminobenzenesulfonamide)
group using the TFA-TFE procedure to furnish the target
purines (30−35) in good overall yields (Scheme 1).
The 6-ethynylpurine derivatives (41 and 42) were
synthesized from the THP-protected 6-chloro-2-fluoropurine
(36)35 via a Sonogashira alkynylation approach (Scheme 2).
Coupling of triisopropylacetylene with 36, employing Pd-
(PPh3)2Cl2/CuI, afforded the protected 6-ethynylpurine (37)
in excellent yield, and removal of the N9-THP group to give 38
and introduction of the 2-arylamino substituent proceeded in
the manner described above to give 39 and 40. Removal of the
TIPS group to furnish the target 2-arylamino-6-ethynylpurines
41 and 42 was achieved under standard conditions. The 6-
propynyl- and 6-phenylethynyl-purine derivatives 48 and 49
were accessible from the guanine derivative 15 by sequential
chlorination at the purine 6-position (44), THP protection
(45), introduction of the appropriately substituted ethynyl
group under Sonogashira conditions (46, 47), and final N9-
deprotection to furnish the target purines 48 and 49 (Scheme
1). The 6-ethylpurine derivative (52) was readily obtained by
reduction of the 6-ethynyl group of the THP derivative 43 with
Lindlar’s catalyst-quinoline to afford 50, with N9-deprotection
(51) and final introduction of the 2-(4-aminobenzenesulfona-
mide) group, giving 52 in modest overall yield.
Scheme 1a
aReagents and conditions: (i) aq HBF4, NaNO2, −15 to 0 °C; (ii) Pd(OH)2, HCO2NH4, MeOH, reflux; (iii) ArNH2, TFA, TFE, 90 °C; (iv) POCl3,
PhNMe2, reflux; (v) 3,4-2H-dihydropyran, (rac)-camphorsulfonic acid, EtOAc, 75 °C; (vi) R-CCH, PdCl2(MeCN)2, dicyclohexyl-(2′,4′,6′-
triisopropyl-[1,1′-biphenyl]-2-yl)phosphine, Cs2CO3, MeCN; (vii) TFA, i-PrOH, H2O, reflux; (viii) DABCO, DMSO, 25 °C. (ix) For 18, 19, 22:
ROH, Na, reflux. For 20, 21, 23: ROH, NaH, DMSO, 25 °C. For definition of R groups, see Table 1.
Scheme 2a
aReagents and conditions: (i) 3,4-2H-dihydropyran, (rac)-camphor-
sulfonic acid, EtOAc, 75 °C; (ii) (i-Pr)3SiCCH, Pd(PPh3)2Cl2, CuI,
Et3N, THF, 25 °C; (iii) TFA, i-PrOH, H2O, reflux; (iv) PhNH2 or 4-
NH2C6H4SO2NH2, TFA, TFE, 90 °C; (v) (n-Bu)4NF, THF, 25 °C;
(vi) Lindlar’s catalyst, quinoline, H2, EtOAc, RT, 2 h; (vii) RB(OH)2
or RBF3K, Pd(OAc)2, dicyclohexyl(2′,6′-dimethoxybiphenyl-2-yl)-
phosphine, K3PO4, PhMe, H2O, 100 °C. For definition of R groups,
see Table 1.
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Efforts to synthesize the 6-cyclopropylpurine (55) employing
Suzuki−Miyaura conditions were unsuccessful, likely due to
competing protodeboronation of the cyclopropylboronic acid
under the reaction conditions employed. This problem was
successfully addressed as reported in the literature by
converting the cyclopropylboronic acid into the corresponding
potassium trifluoroborate,36 whereby coupling to the THP-
protected 6-chloro-2-fluoropurine (36) occurred to furnish 53
in acceptable yield. Subsequent transformation into the target
6-cyclopropylpurine (55) was achieved readily. The introduc-
tion of aryl substituents at the purine 6-position was achieved
using Suzuki−Miyaura cross-coupling chemistry with 6-chloro-
2-fluoropurine derivative 36 (Scheme 2). Optimization of the
reagents and reaction conditions employed for the cross-
coupling step enabled the preparation of a defined series of 2-
fluoro-6-arylpurine derivatives (56−62) in excellent yields, and
conversion into the requisite 6-aryl-2-(4-sulfonamidophenyl)-
aminopurines (70−76) proceeded smoothly under the
previously described conditions.25,33
The synthesis of prospective CDK2 inhibitors encompassing
alternative heterocyclic systems was undertaken as summarized
in Scheme 3. In each case, the parent chloroheterocycles (77,
84, 85, 92, 99) were synthesized by adapting literature
procedures37−41 and the cyclohexylmethyl substituent intro-
duced by treatment with the corresponding alkoxide, with N9
protected where necessary, as described previously. Iodination
(81)42 or chlorination (88, 89, 96) of the respective 2-
aminoheterocycles under Sandmeyer conditions facilitated
introduction of the 2-arylamino group under the standard
TFA-TFE conditions (88, 89) or employing a Buchwald
amination procedure (81, 96), followed by deprotection as
necessary to afford the target compounds 83, 90, 91, and 98.
The imidazo[1,2-a]pyrimidine derivatives (101, 102) were
prepared from 5,7-dichloroimidazo[1,2-a]pyrimidine (99)43,44
by regioselective 5-alkoxylation to give 100, followed by final
introduction of the arylamino group at the 7-position under
TFA-TFE conditions. Given the possibility of alkoxide attack at
the 7-position of 99 to furnish the alternative regioisomer, the
structure of 102 was unambiguously confirmed by X-ray
crystallography (Supporting Information).
■ RESULTS AND DISCUSSION
The chemical structures, CDK inhibitory activity, and in vitro
antitumor activity for the purine derivatives and alternative
heterocycles are summarized in Tables 1−3, with the values for
compounds 1−3 included for comparative purposes.
Structure−Activity Relationships. The importance of a
substituent at the purine 6-position was reaffirmed by the
simple 2-amino- and 2-phenylamino-purines (8 and 12), where
a dramatic reduction in potency was observed compared with
the parent 6-cyclohexylmethoxy derivatives 1 and 2, respec-
tively. A similar effect was also evident for the sulfanilylpurine
13, which was some 300-fold less active than 3. These results
are consistent with the putative interaction of this inhibitor
class with the ATP-binding site of CDK2, which requires that
the 6-substituent occupies a lipophilic pocket close to the ribose
binding site, thereby orienting the purine to make the triplet of
hydrogen bonds with the hinge region.24 The low-micromolar
potency of the 2-sulfanilyl derivative 13 likely reflects the
contribution to binding arising through additional interactions
Scheme 3a
aReagents and conditions: (i) PMB-Cl, K2CO3, DMF, 80 °C; (ii) NaH, cyclohexylmethanol, DMSO, 25 °C; (iii) TFA, 80 °C; (iv) CH2I2, iso-amyl
nitrite, CuI, THF, 80 °C; (v) sulfanilamide, Pd2(dba)3, XPhos, K2CO3, MeCN, 80 °C; (vi) LiCl, iso-amyl nitrite, SOCl2, DMA or THF, 0−25 °C;
(vii) ArNH2, TFA, TFE, 90 °C; (viii) SEM-Cl, NaH, MeCN, 0 °C; (ix) TBAF, THF, 25 °C.
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between the arylsulfonamide group of 13 with the CDK2
surface adjacent to the ATP binding site on the C-terminal lobe
(termed the “specificity surface”) despite the absence of a 6-
substituent. Perhaps not surprisingly, the guanine derivatives 15
and 16 were only weakly active, attributable to unfavorable
interactions between the 6-oxo functionality and the ribose-
binding pocket. These derivatives also exhibited the very poor
aqueous solubility characteristic of many guanine derivatives.
Replacement of the 6-cyclohexylmethoxy group of 3 by
smaller alkoxy substituents proved informative and was broadly
consistent with our earlier investigations with derivatives of 1.31
In that study, 2-amino-6-methoxypurine (O6-methylguanine)
demonstrated negligible activity (CDK2; IC50 > 100 μM), and
the relatively poor chemical stability of this purine militated
against preparing the corresponding 2-sulfanilyl analogue. The
6-ethoxypurine 30 exhibited high CDK2 inhibitory activity
(IC50 = 26 nM), with an approximately 3-fold increase in
potency being observed for the n-propoxy- (31; IC50 = 8 nM)
and iso-propoxy- (32; IC50 = 10 nM) derivatives. Potency was
improved further by increasing the size of the 6-alkoxy group,
as demonstrated by the activity of the isomeric butoxy
analogues 33 and 34 with IC50 values of 3 and 1 nM,
respectively. The relationship between the bulk of the 6-alkoxy
group and the CDK2-inhibitory activity generally parallels that
previously observed for the corresponding 2-amino-6-alkox-
ypurines, albeit that the sulfanilylpurines 30−34 are several
orders of magnitude more potent. For example, 34 (IC50 = 1
nM) is approximately 50000-fold more potent than the
corresponding 2-amino-6-sec-butoxypurine (CDK2; IC50 = 49
± 7 μM),31 again corroborating the crucial binding
Table 1. Chemical Structures and CDK2-Inhibitory Activity of Purine Derivatives
aIC50 values were determined in accordance with previously described methods.
20,23 bData shown are the mean of at least two independent
experiments ± standard deviation. cPercent inhibition values are in brackets. dThe oxo-tautomers predominate.
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contribution made by the arylsulfonamide function. A
propargyloxy group at the purine O6-position conferred activity
comparable to the ethoxy derivative (compare 35 and 30), in
keeping with the trend reported previously for the 2-amino-6-
alkoxypurine series.31
The introduction of an ethyl substituent at the purine 6-
position (52) reduced CDK2-inhibitory activity some 10-fold
compared with the 6-ethoxypurine (30), and very modest
potency was also observed for the 6-ethynyl derivatives 41 and
42. Although 6-alkoxy and 6-alkyl groups differ with regard to
both their electronic and steric character, as well as lipophilicity,
the high potency of the 6-triisopropylsilyethynylpurine (40;
IC50 = 17 nM) shows that steric bulk, as well as electronic
factors, is an important feature for binding in the ribose pocket
of CDK2. The modest improvement in potency observed for
the prop-1-ynyl (48) and phenylethynyl (49) derivatives
compared with the parent 6-ethynylpurine 41 also suggests
that the overall shape of the 6-substituent is an important factor
for occupancy of the ribose-binding pocket, supported by the
activity of the 6-cyclopropylpurine 55 (IC50 = 19 nM). These
data also suggest that the oxygen atom of the 6-alkoxypurines,
which would act as a weak hydrogen bond acceptor, does not
make a significant contribution to binding affinity.
The potency of the 6-phenylpurine (70; IC50 = 24 nM)
prompted further elaboration, with comparable activity residing
in the 3-methoxyphenyl (71), 4-methoxyphenyl (72), and 6-(3-
phenylphenyl)purine (73) derivatives. By contrast, the
piperonyl derivative (74) was some 20-fold less potent than
70, and the introduction of still larger groups was detrimental,
as evident from the very weak CDK2 inhibitory activity of the
dibenzofuran-1-yl (75) and thianthren-1-yl (76) analogues.
The bulkier bicyclic and tricyclic heteroaromatic rings of these
purines are presumably poorly accommodated within the
ribose-binding pocket. It is of interest to note that the CDK2
inhibitory activity of the 6-unsubstituted derivative 13 is
equipotent with 75 and superior to that of 76, implying that the
6-substituents of these purines make a negligible binding
contribution.
With a view to assessing selectivity for CDK2, selected purine
derivatives were evaluated against a panel of CDKs (Table 2).
As expected, removal of the 6-cyclohexylmethyl substituent of
3, which makes a number of interactions with the conserved
ATP ribose binding site to furnish 13 compromised potency
against all the CDKs evaluated, although the effect was less
pronounced against CDK2.
The 6-alkoxypurines 34 and 35 exhibited good selectivity for
CDK2 over the closely related CDK1 (80-fold and 50-fold,
respectively), with 34 retaining selectivity over CDKs 4, 7, and
9 comparable with 3. A similar profile was observed for the 6-
phenylpurine 70, which was some 30-fold selective for CDK2
over CDK1. By contrast, the 6-([1,1′-biphenyl]-3-yl)purine
derivative 73 exhibited a very interesting CDK selectivity
profile, proving some 2000-fold selective for CDK2 over CDK1
while exhibiting only weak inhibitory activity against CDKs 4, 7,
and 9. To the best of our knowledge, this level of selectivity for
CDK2 over CDK1 is unprecedented.
Modification of the core purine heterocycle of 1 and 3
afforded further interesting results (Table 3). A comparison of
2-amino-6-cyclohexylmethylpurine 1 with the alternative
heterocycles 86, 87, and 93 revealed that although these
compounds exhibited comparable potency against CDK2,
activity against other CDK family members was markedly
attenuated. The very weak activity of the imidazopyrimidine
derivatives 101 and 102 is not surprising given the absence of
the requisite donor−acceptor−donor motif and presumably
reflects the combined influence arising from the absence of the
N1 and N7 functions found in the corresponding purine
derivatives 1 and 3. The modest CDK inhibition profile of
imidazopyridine 83 indicates that removal of the N1 nitrogen is
detrimental to CDK inhibitory activity. However, with the
exception of the imidazopyridine (83) and imidazopyrimidine
(102) derivatives, modification of the core purine heterocycle
of 3 was generally tolerated without a marked loss of CDK2
inhibitory activity. Thus, triazolopyrimidine (90) analogue is
2.5-fold more potent than 3, while pyrazolopyrimidine (91)
and pyrrolopyrimidine (98) analogues proved only some 4−5-
fold less potent than 3 against CDK2 and retained good
selectivity over all other CDK family members examined.
Notably, derivatives 91 and 98 were approximately 100-fold
selective for CDK2 over CDK1.
Cellular Studies. The ability of compounds to inhibit
cellular proliferation was examined in a 5-day growth assay
using five histologically distinct retinoblastoma protein (Rb)-
proficient human tumor lines (A375 melanoma, Calu-6 lung
carcinoma, MDA-MB-231 breast adenocarcinoma, SJSA1
osteosarcoma, and SKUT-1B uterine corpus leiomyosarcoma).
While compound 73 demonstrated appreciable nanomolar
potency versus CDK2 in isolated kinase assays, the maximal
concentration tested in cellular assays (30 μM) had no or
limited effects on the growth of cells, thereby preventing the
concentration that induced a 50% growth inhibitory (GI50)
effect to be determined (data not shown). In contrast,
compounds 91 and 98, which were only 2.4- and 1.7-fold
more potent respectively in CDK2 kinase assays, dose-
dependently inhibited the growth of each tumor cell line with
GI50 values ranging from 1−22 μM. The cellular activity of
Table 2. CDK Selectivity and Cellular Activity for Selected
Compounds
aIC50 values were determined in accordance with previously described
methods.20,23 bData shown are the mean of at least two independent
experiments ± standard deviation. cPercent inhibition values are in
brackets.
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these compounds compared favorably to that of compound 3
(Figure 1).
Structure Determination. Compounds within this series
show greater activity toward CDK2 than CDK1, generally
varying between 10- and 80-fold (Table 2). However, 73
exhibits exceptional discrimination being a ca. 2000-fold more
potent inhibitor of CDK2. To confirm the binding mode and to
identify potential interactions that might explain the selectivity
of 73 for CDK2 over CDK1, 73 and 3 were cocrystallized with
CDK2-cyclin A and CDK1-cyclin B-cyclin-dependent kinases
regulatory subunit 2 (CKS2), respectively. The poor potency of
73 toward CDK1 appears to preclude determination of a
CDK1-cyclin B-CKS2−73 cocomplex structure, as despite
repeated attempts we were unable to visualize the compound in
the active site. The statistics for the data sets and for the
crystallographic refinements are presented in Table 4.
Compound 73 emulates the interactions made by 3 within
the CDK2 active site (Figure 2A).24 Indeed, the purine and
aniline rings of each inhibitor superimpose very well. The
purine rings occupy the CDK2 ATP binding site, and each
makes a triplet of hydrogen bonds with the backbone carbonyl
of Glu81 and the amide NH and carbonyl moieties of Leu83
within the hinge sequence (Figure 2A). The respective anilino
rings project out of the CDK2 catalytic site so that the
sulfonamide NH2 group and one of the oxygens in each make
hydrogen bonds with the side chain and backbone nitrogen of
Asp86, respectively.
The structures of 73 and 3 differ in the substitution present
at the purine C-6 position. The O6-cyclohexylmethyl
substituent of 3 occupies the ATP ribose binding pocket and
is complementary in shape and forms favorable hydrophobic
interactions with an apolar pocket created by the conformation
of the CDK2 glycine-rich loop (residues 9−19).24 This loop
adopts an identical backbone structure when bound to 73 so
that the purine-proximal phenyl ring emulates the position of
the cyclohexylmethyl substitutent of 3. The distal phenyl ring
substituted at the meta position can then be comfortably
accommodated as it twists toward the aniline moiety (Figure
2A). In contrast, para substitutions of the purine-proximal
phenyl ring exemplified by 72, 74, 75, and 76 (Table 1) would
Table 3. Chemical Structures and CDK Inhibitory Activity of Other Heterocyclic Derivatives
aIC50 values were determined in accordance with previously described methods.
20,23 bData shown are the mean of at least two independent
experiments ± standard deviation. cPercent inhibition values are in brackets. dValue determined at 100 μM.
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be directed out of the CDK2 active site toward the tip of the
glycine-rich loop. Smaller substitutions, for example a methoxy
in 72 can be accommodated but larger ring systems as
exemplified by 74 and 76 lead to considerable drops in potency,
suggesting they may sterically clash with the CDK2 structure in
this region (Table 1).
To probe further the binding mode of the series, CDK1-
cyclin B-CKS2 was cocrystallized with 3 (Figure 2B). This
structure shows that the purine backbone emulates the
interactions made by this inhibitor within the CDK2 binding
site and that the O6-cyclohexylmethyl substituent occupies the
ribose binding pocket. As previously reported,46 inhibitor
binding within the ATP binding site is accompanied by minor
remodelling of the CDK1-cyclin B into a conformation
compatible with catalysis.
All of the side chains contacted by 73 in the co-complex with
CDK2-cyclin A are conserved in CDK1 so that selectivity must
derive from indirect readout of remote sequence differences.
One mechanism by which such differences can impact inhibitor
binding is where they shape the conformational energy
landscape, permitting conformations in one kinase that are
precluded in another. As described above, the glycine-rich loop
makes a significant contribution to the catalytic cleft, shaping
the binding site that accommodates the purine C-6
substituents. We note that the glycine-rich loop in the
CDK2-cyclin A−73 structure adopts a conformation in which
Tyr15 is folded into the active site, contacting residues of the
C-helix (Figure 2C). This position for the side chain of Tyr15 is
seen in a number of other CDK2-cyclin A−inhibitor complexes,
suggesting that it reflects a preferred conformation of CDK2.
However, in available structures of apo CDK1-cyclin B, and
CDK1-cyclin bound to compound 2346 or 3 (this paper), a
comparable location for the side chain of Tyr15 has not been
observed (Figure 2C). We speculate, therefore, that 73 binds
more tightly to CDK2 than to CDK1 because in doing so, it
Figure 1. Activity of compounds 3, 91, and 98 against tumor cell growth.45 Rb-proficient human tumor cell lines were incubated for 120 h with
compounds and cellular protein determined by SRB assay. Dose−response curves and GI50 bar charts represent the mean ± SEM from three or four
independent experiments.
Table 4. X-ray Data Collection and Refinement Statistics
CDK2-cyclin A−
73a CDK1-cyclin B-CKS2−3a
Data Collection
space group P212121 P1
unit cell (Å) a = 73.5,
b = 132.1,
c = 149.2
a = 65.0, b = 67.8, c = 85.1,
α = 103.9, β = 90.9, γ = 90.4
resolution (Å) 66.03−2.97 65.76−2.06
(highest
resolution shell)
(3.13−2.97) (2.10−2.06)
total observations 226370 (7244) 169709 (8389)
unique 30773 (1098) 84841 (4161)
Rmerge
a 0.086 0.092
mean I/σ(I) 6.7 (1.6) 6.2 (1.2)
completeness % 100 (99.7) 97.3 (95.5)
Refinement
total number of
atoms
protein 8927 20449
other 64 100
waters 18 291
R (highest
resolution shell)
0.213 0.198
Rfree (highest
resolution shell)
0.266 0.254
rmsd bonds (Å) 0.0122 0.0217
rmsd angles (deg) 1.770 2.233
aThe structures have been deposited in the PDB with accession codes
5LQE (CDK2-cyclin A−73) and 5LQF (CDK1-cyclin B-CKS2−3).
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stabilizes a glycine-rich loop conformation that is preferred in
CDK2 but not in CDK1.
■ CONCLUSIONS
Novel 6-substituted 2-(4′-sulfamoylanilino)purines have been
designed as competitive inhibitors acting at the ATP binding
site of CDK2 with particular attention being given to
abrogating activity against CDK1. A variety of substituents
were explored, either attached directly to C-6 or via an oxygen
link, in the context of their possible interaction with a lipophilic
pocket close to the ATP ribose binding site. The relationship
between the size of a 6-alkoxy group and CDK2-inhibitory
activity was found to parallel that previously observed for the
corresponding 2-amino-6-alkoxypurines. In general, the new
compounds were significantly less potent (typically 10−80×)
against CDK1 than CDK2. Most impressive was 4-((6-([1,1′-
biphenyl]-3-yl)-9H-purin-2-yl)amino) benzenesulfonamide that
was ∼2000-fold less active toward CDK1 (IC50 86 μM), while
retaining high potency against CDK2 (0.044 μM). Compounds
substituted with relatively large conformationally constrained
groups, e.g. bicyclic and tricyclic aromatic systems, showed
greatly reduced inhibitory activity, indicating poorly accom-
modation of these substituents in the lipophilic binding site.
Analogues of 6-cyclohexylmethoxy-2-(4′-sulfamoylanilino)-
purine, in which the purine ring was replaced by a
triazolopyrimidine, pyrazolopyrimidine or pyrrolopyrimidine
were only marginally less active against CDK2 than the parent
purine. However, replacement with an imidazopyridine or
imidazopyrimidine gave much less potent derivatives. Co-
crystal structures of inhibitors bound to CDK2 and CDK1
revealed that the binding mode of the purine-based inhibitor
series is conserved. We show that inhibitor binding to CDK2
stabilizes a glycine-rich loop conformation that shapes the ATP
ribose binding pocket, resulting in effective inhibition of CDK2.
We propose that this region of the active site might be the basis
of the design of further inhibitors differentiating between
CDK1 and CDK2.
■ EXPERIMENTAL SECTION
General Synthetic Procedures. Chemicals and solvents were
obtained from standard suppliers. Solvents were either dried by
standard techniques or purchased as anhydrous. Reactions needing
microwave irradiation were carried out in an Initiator Sixty Biotage
apparatus. Petrol refers to petroleum ether (bp 40−60 °C, reagent
grade, Fisher Scientific). All reactions that required inert or dry
atmosphere were carried out under a blanket of nitrogen, which was
dried by passage through a column of phosphorus pentoxide.
Glassware was dried in an oven prior to use. Column chromatography
was carried out using 40−60 μm mesh silica in glass columns under
medium pressure or with a Biotage SP4 flash purification system using
KP-Si. Thin layer chromatography (TLC) was performed on 20 mm
precoated plates of silica gel (Merck, silica gel 60F254); visualization
was achieved using ultraviolet light (254 nm). NMR spectra were
recorded on a Bruker Spectrospin AC 300E (300 MHz) NMR
Spectrometer or Bruker BioSpin UltraShield Plus 500 MHz using
deuterated solvent as a lock. IR spectra were recorded on a Bio-Rad
FTS 3000MX diamond ATR, and UV analysis was performed using a
Hitachi U-2000 spectrophotometer. LC-MS analysis was carried out
on a Micromass Platform instrument operating in positive and
negative ion electrospray mode, employing a 50 mm × 4.6 mm C18
column (Supelco Discovery or Waters Symmetry) and a 15 min
gradient elution of 0.05% formic acid and methanol (10−90%).
HRMS were measured using a Finnigan MAT 95 XP or a Finnigan
MAT 900 XLT by the EPSRC National Mass Spectrometry Service
Centre (Swansea). The purity of final compounds was assessed by
reversed-phase HPLC; all tested compounds were >95% purity. HPLC
instrument, Agilent 1200 equipped with a photodiode array detector
(190−400 nm). Sample temperature, ambient; injection volume, 5 μL;
flow rate, 1 mL/min. 5−100% MeCN gradient over 9 min and an
isocratic hold at 100% MeCN for 2.5 min, before returning to initial
conditions. Mobile phase A = 0.1% ammonia in water or 0.1% formic
acid in water, mobile phase B = MeCN. Column: Waters XSELECT
CSH C18, 3.5 μm, 4.6 mm × 150 mm or Waters XTerra RP18, 5 μm,
4.6 mm × 150 mm. Column maintained at ambient temperature.
General Procedure A. To a stirred suspension of the appropriate
haloheterocycle (1.0 mol equiv) and 4-aminobenzenesulfonamide (2.0
mol equiv) in TFE (25 mL/g of haloheterocycle) was added TFA (2.5
mL/g of haloheterocycle) dropwise. The resulting solution was heated
under reflux for 12−48 h under a nitrogen atmosphere. The solvent
was removed in vacuo, and the residue was redissolved in EtOAc (10−
20 mL). The solution was washed with saturated aqueous sodium
bicarbonate solution (3 × 10 mL), and the aqueous extracts were
combined and washed with EtOAc (2 × 15 mL). The combined
organic layers were dried (Na2SO4) and the solvent removed under
reduced pressure to give a residue that was purified in the manner
indicated.
6-Chloro-2-fluoro-9H-purine (10).47 To a stirred solution of HBF4
(48% aqueous, 120 mL) at 0 °C was added 2-amino-6-chloropurine
(9) (6.0 g, 35.0 mmol). Over 20 min, a solution of NaNO2 (4.9 g, 70.0
Figure 2. Structures of CDK2-cyclin A−73 and CDK1-cyclin B-
CKS2−3. (A) Surface representation of CDK2 (ice-blue) bound to
cyclin A (coral) in complex with 73 (yellow). The inset shows the
interactions of 73 within the ATP site of CDK2-cyclin A. (B) Surface
representation of CDK1 (dark-cyan) bound to cyclin B (pale-crimson)
and CKS2 (lemon) in complex with 3 (green). The inset shows the
interactions of 3 within the ATP site of CDK1-cyclin B-CKS2. In (A)
and (B), the protein backbone is rendered in ribbon representation
and selected CDK2 and CDK1 residues are drawn respectively with
carbon atoms colored ice-blue and dark-cyan. The hydrogen bonds are
shown as black dotted lines. (C) The structural conformations of the
CDK2-cyclin A and CDK1-cyclin B-CKS2 glycine-rich loops to
illustrate the alternative poses of catalytic residue Tyr15. The left-hand
side panel compares CDK2-cyclin A in complex with 73 (ice-blue) to
other inhibitor bound CDK2-cyclin A complexes (PDB entries 4EOS
(green), 3TNW (coral), and 3MY5 (lilac)). The right-hand panel
overlays CDK1-cyclin B-CKS2 bound to 3 (ice-blue) with apo CDK1-
cyclin B-CKS2 (PDB entry 4YC3, lilac) and CDK1-cyclin B-CKS2 in
complex with compound 23 (PDB entry 5HQ0, green). The
conformations of the loop when CDK1 is bound to 3 or compound
23 cannot be distinguished. Gly-rich loop, glycine-rich loop.
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mmol) in water (200 mL) was added dropwise, ensuring the
temperature remained close to 0 °C. The pale-yellow solution was
raised to room temperature and stirred for 18 h. The resulting solution
was neutralized to pH 7 in an ice bath at 0 °C by addition of Na2CO3
(6.00 g) in water (200 mL). Solvents were removed in vacuo, and the
residual solid was redissolved in MeOH (100 mL) and adsorbed onto
silica (250 mL). The crude material was purified by chromatography
(silica; 10% MeOH:DCM) to afford 10 as a white crystalline solid
(4.52 g, 75%); mp 171−173 °C (lit.,47 mp 174 °C); UV λmax (EtOH)
393 nm. IR (cm−1) 2964, 2785, 1735, 1581. 1H NMR (500 MHz,
DMSO-d6) δ 8.60 (1H, s, H-8), 13.9 (1H, s, NH). LRMS (ES
+) m/z
172.6 [M + H]+.
2-Fluoro-9H-purine (11).48,49 To a stirred suspension of 6-chloro-
2-fluoropurine (10) (0.30 g, 1.74 mmol) and palladium hydroxide on
carbon (20% w/w, 0.30 g) in methanol (15 mL) was added
ammonium formate (0.34 g, 5.35 mmol). The suspension was heated
under reflux for 1 h before filtering through a pad of Celite, eluting
with methanol (20 mL). Removal of volatiles under reduced pressure
afforded 11 as a white solid (240 mg, 100%); mp 219 °C (dec.) (lit.,48
decomposed at 216 °C). 1H NMR (300 MHz, DMSO-d6) δ 8.60 (1H,
s, H-8), 9.01 (1H, s, H-6), 13.9 (1H, s, NH). LRMS (ES+) m/z 139.2
[M + H]+.
Phenyl-(9H-purin-2-yl)amine (12). Prepared from aniline (0.18
mL, 2 mmol) and 2-fluoro-9H-purine (11, 0.138 g, 1.0 mmol) in
accordance with general procedure A. The reaction mixture was stirred
under reflux for overnight. After removal of the solvent in vacuo, the
residue was dissolved in EtOAc (10−30 mL), washed with saturated
aqueous NaHCO3 (3 × 30 mL), and dried (MgSO4). The crude
material was purified by chromatography (silica; 0−20%
MeOH:DCM), followed by recrystallization from DCM to afford 12
as an off-white solid (65 mg, 31%); Rf 0.20 (5% MeOH:DCM); mp
200−201 °C; UV λmax (EtOH) 328, 270, 239, 206 nm. IR (cm−1)
3234, 3103, 2804, 1624, 1602, 1539, 1402, 1292, 1217. 1H NMR (300
MHz, DMSO-d6) δ 6.91 (1H, t, J = 7.5 Hz, H-4′), 7.28 (2H, t, J = 7.5
Hz, H-3′ and H-5′), 7.83 (2H, d, J = 9.0 Hz, H-2′ and H-6′), 8.82 (1H,
s, H-6), 8.24 (1H, s, H-8), 9.53 (1H, s, NH), 12.9 (1H, s, NH). LRMS
(ES+) m/z 212.0 [M + H]+. HRMS calcd for C11H10N5 [M + H]
+
212.0931, found 212.0933.
4-(9H-Purin-2-ylamino)benzenesulfonamide (13). Prepared fol-
lowing general procedure A from 2-fluoro-9H-purine (11, 0.10 g,
0.725 mmol). Recrystallization from MeOH:H2O gave 13 as a pale-
white solid (74 mg, 35%); Rf 0.40 (20% MeOH:DCM); mp >320 °C
(dec); UV λmax (EtOH) 287, 213 nm. IR (cm
−1) 3223, 1585, 1481,
1307, 1251, 1148, 1091. 1H NMR (300 MHz, DMSO-d6) δ 7.17 (2H,
s, SO2NH2), 7.73 (2H, d, J = 9.0 Hz, H-3′ and H-5′), 7.99 (2H, d, J =
9.0 Hz, H-2′ and H-6′), 8.33 (1H, s, H-6), 8.00 (1H, s, H-8), 10.00
(1H, s, NH). LRMS (ES+) m/z 291.0 [M + H]+. HRMS calcd for
C11H11N6O2S [M + H]
+ 291.0659, found 291.0659.
N2-Phenylguanine 2,2,2-trifluoroacetate (15). The title compound
was prepared following general procedure A using 2-bromohypox-
anthine (14, 1.00 g, 4.7 mmol) and aniline (0.9 mL, 9.40 mmol) to
yield 15 as a white solid (1.17 g, 73%). The isolated compound was
pure by analytical HPLC without the need for further purification; mp
229−231 °C; UV λmax (EtOH) 273 nm. IR (cm−1) 3332, 3128, 2943,
2756, 2555, 2387, 1678, 1572. 1H NMR (300 MHz, DMSO-d6) δ 7.07
(1H, t, J = 7.5 Hz, H-4′), 7.36 (2H, dd, J = 7.5, 8.0 Hz, H-3′ and H-5′),
7.62 (2 H, d, J = 8.0 Hz, H-2′ and H-6′), 7.94 (1H, s, H-8), 8.46 (1H,
br s, NH), 9.00 (1H, br s, NH). 13C NMR (75 MHz, CDCl3) δ 113,
120, 123, 129, 138, 139, 150, 152, 155. LRMS (ES+) m/z 228.3 [M +
H]+. HRMS calcd for C11H10N5O [M + H]
+ 228.0881, found
228.0880.
6-Oxo-2-((4-sulfamoylphenyl)amino)-6,9-dihydro-1H-purine
2,2,2-trifluoroacetate (16). Synthesized in accordance with general
procedure A from 2-bromohypoxanthine (14, 0.10 g, 0.47 mmol) to
yield 16 as an amorphous white solid (60 mg, 42%); mp >300 °C; UV
λmax (EtOH) 275 nm. IR (cm
−1) 3348, 3113, 2990, 2877, 2792, 2333,
1672, 1575, 1365, 1153. 1H NMR (300 MHz, DMSO-d6) δ 7.28 (2H,
s, SO2NH2), 7.79 (4H, m, H-2′, H-3′, H-5′ and H-6′), 8.31 (1H, s, H-
8), 9.25 (1H, br s, NH), 10.84 (1H, br s, NH). 13C NMR (75 MHz,
CDCl3) δ 113, 120, 123, 127, 138, 139, 150, 152, 156. LRMS (ES
+)
m/z 307.3 [M + H]+.
1-(2-Amino-9H-purin-6-yl)-4-aza-1-azoniabicyclo[2.2.2]octane
(17).34 1,4-Diazabicyclo[2.2.2]octane (9.90 g, 88.4 mmol) was added
to a solution of 2-amino-6-chloropurine 9 (5.00 g, 29.5 mmol) in
DMSO (100 mL) over 1 h, and the mixture was stirred at room
temperature for 24 h. The resulting white precipitate was filtered and
washed with diethyl ether. The solid was suspended in DCM (200
mL) and stirred for 1 h. After filtration and washing with DCM several
times, 9 was obtained as a white solid, which was dried in vacuo (7.95
g, 96%) and used without further purification; mp 230 °C (dec) (lit.,34
decomposed at 230 °C). 1H NMR (300 MHz, D2O) δ 3.31 (6H, t, J =
7.5 Hz, (N(CH2)3), 4.07 (6H, t, J = 7.5 Hz, (N
+(CH2)3), 8.13 (1H, s,
H-8). 13C NMR (75 MHz, D2O) δ 38.7, 53.4, 116.0, 143.7, 151.3,
158.4.
General Procedure B. 2-Amino-6-chloropurine (9, 1.0 mol equiv)
was added to a solution prepared from metallic sodium (5.0 mol
equiv) dissolved in the appropriate alcohol (3.4 mL/mmol). The
mixture was stirred at reflux until LCMS analysis indicated the absence
of starting materials (3−24 h). After cooling, the reaction mixture was
neutralized with glacial AcOH and the volatile material was removed in
vacuo. Unless otherwise indicated, purification was achieved either by
recrystallization from H2O or by adding H2O to the reaction mixture
and extracting the product into EtOAc (3 × 100 mL), followed by
drying (MgSO4) and removal of the solvent in vacuo.
General Procedure C. The appropriate alcohol (4.0 mol equiv) was
added dropwise to a stirred suspension of NaH (3.0 mol equiv) in
DMSO (2.5−3.0 mL/mmol), and the resulting mixture was stirred for
1−2 h. To this was added DABCO-purine (17, 1.0 mol equiv) or the
appropriate haloheterocycle (1.0 mol equiv), and the mixture was
stirred for 24 h with heating as specified. Water (20−200 mL) was
added, and the basic emulsion was neutralized with glacial acetic acid.
The aqueous phase was extracted with EtOAc (3 × 50−100 mL), and
the organic layers were washed with saturated aqueous NaCl (100
mL). The combined organic layers were dried (MgSO4) and
concentrated in vacuo to yield the crude product, which was purified
by chromatography on silica and/or recrystallization from an
appropriate solvent.
General Procedure D. To a stirred solution of hydrofluoroboric
acid (50%, aq, 20.0 mol equiv) cooled below −20 °C was added the
appropriate 2-amino-6-alkoxypurine (1.0 mol equiv). While maintain-
ing the temperature at −15 °C, a solution of NaNO2 (2.0 mol equiv)
in H2O (1−3 mL/mmol NaNO2) was added dropwise over 10 min.
The mixture was stirred at room temperature for 3 h and neutralized at
−15 °C by the dropwise addition of 15% (w/v) aqueous Na2CO3
solution, and the precipitated solid was collected by filtration and
washed with H2O. The residual solid was triturated with EtOAc (3 ×
100 mL) and filtered. The combined filtrates were concentrated under
reduced pressure to furnish the product, which was purified as
indicated.
General Procedure E. The appropriate 9-(tetrahydro-2H-pyran-2-
yl)-9H-purine (1.0 mol equiv) was dissolved in 2-propanol (60 mL/g)
and deionized water (20 mL/g). Trifluoroacetic acid (10.0 mol equiv)
was added, and the reaction mixture was stirred at 100 °C for 2 h and
cooled to room temperature, and the solution was adjusted to pH 8 by
addition of conc aqueous ammonia solution. The volume of solvent
was reduced by 50% under reduced pressure; if a precipitate resulted,
this was collected and washed with 2-propanol (2 × 10 mL). If
precipitation was not observed following neutralization, the reaction
mixture was partitioned between EtOAc (20 mL) and saturated
aqueous NaCl solution (20 mL) The organic layer was dried
(Na2SO4) and evaporated under reduced pressure, and the product
was purified by chromatography as specified.
General Procedure F. Tetrabutylammonium fluoride solution (1.0
M in THF, 1.5 mol equiv) was added dropwise to a stirred solution of
the appropriate 6-triisopropylsilylethynylpurine (1.0 mol equiv) in
anhydrous THF (10−20 mL), and the mixture was stirred for 5−15
min at ambient temperature under N2. Volatiles were evaporated
under reduced pressure, and the residue was redissolved in EtOAc
(100 mL/g) and washed with saturated aqueous NaCl (100 mL/g),
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and the organic fraction was removed in vacuo. The product was
purified as described.
General Procedure G. An oxygen-free solution of the required
boronic acid or potassium trifluoroborate salt (1.09 mmol), the
appropriately 2-substituted 6-chloro-9-(tetrahydro-2H-pyran-2-yl)-9H-
purine (0.78 mmol), dicyclohexyl(2′,6′-dimethoxybiphenyl-2-yl)-
phosphine (SPhos) (2.5 mol %), and palladium acetate (1.0 mol %)
in toluene (4 mL) was degassed by bubbling nitrogen through the
solution in a sealed vial for 5 min. To the pale-yellow solution was
added K3PO4 (1.56 mmol) and water (approximately 50 μL). The
solution was again degassed for 15 min and subsequently heated to
100 °C for 18 h. The black-brown suspension was filtered through
Celite, eluting with MeOH (3 × 10 mL), and the product was isolated
by chromatography as indicated.
2-Amino-6-ethoxypurine (18).50,51 Treatment of EtOH (100 mL)
with Na (3.38 g, 147.5 mmol), followed by addition of 2-amino-6-
chloropurine 9 (5.0 g, 29.5 mmol) according to general procedure B,
afforded the crude product. Recrystallization from H2O gave 18 as a
white powder (4.75 g, 90%); Rf 0.26 (10% MeOH:DCM), mp 247 °C
(dec) (lit.51 mp 230 °C (dec), lit.50 mp 293 °C (dec)). IR (cm−1)
3321, 2981, 2363, 2143, 1619, 1584, 1508, 1458, 1427, 1396, 1375,
1342, 1285, 1223, 1161, 1118 cm−1. 1H NMR (300 MHz, DMSO-d6)
δ 1.35 (3H, t, J = 7.1 Hz, CH3), 4.44 (2H, q, J = 7.1 Hz, CH2), 6.21
(2H, s, NH2), 7.81 (1H, s, H-8).
13C NMR (75 MHz, DMSO-d6) δ
14.9, 61.6, 160.1. LRMS (ES+) m/z 180.3 [M + H]+. Anal. Found: C,
47.11; H, 4.97; N, 38.97. C7H9N5O requires: C, 46.92; H, 5.06; N,
39.09.
2-Amino-6-n-propoxypurine (19).50,51 Treatment of 1-propanol
(20 mL) with Na (0.68 g, 29.5 mmol), followed by addition of 2-
amino-6-chloropurine 9 (1.0 g, 5.9 mmol) according to general
procedure B, gave the crude product. Recrystallization from H2O
afforded 19 (1.06 g, 93%) as a yellow solid, Rf 0.21 (10%
MeOH:DCM), mp 196−198 °C (lit.51 mp 199−201 °C, lit.50 mp
208 °C). IR (cm−1) 3484, 3389, 3318, 3203, 2965, 2935, 2882, 2522,
2361, 2338, 1578, 1507, 1449, 1398, 1362, 1331, 1276, 1225, 1165,
1119. 1H NMR (300 MHz, DMSO-d6) δ 0.97 (3H, t, J = 7.4 Hz, CH3)
1.76 (2H, tq, J = 7.2, 7.2 Hz, CH3CH2CH2O), 4.34 (2H, t, J = 6.8 Hz,
OCH2), 6.20 (2H, s, NH2), 7.82 (1H, s, H-8), 12.37 (1H, br s, NH).
13C NMR (75 MHz, DMSO-d6) δ 10.7, 22.2, 67.3, 138.5, 160.1, 160.3,
162.2. LRMS (ES+) m/z 194.17 [M + H]+. Anal. Found: C, 46.81; H,
5.95; N, 33.78. C8H11N5O·0.7H2O requires: C, 46.69; H, 6.07; N,
34.03.
2-Amino-6-isopropoxypurine (20).31 Treatment of 2-propanol
(0.85 mL, 14.2 mmol) with NaH (0.26 mg, 10.7 mmol) in DMSO
(10 mL), followed by addition of 17 (1.0 g, 3.6 mmol) was performed
according to general procedure C, to afford the crude product.
Purification by chromatography (silica; 5−10% MeOH:DCM)
afforded 20 as a yellow oil. Trituration of the oil with diethyl ether
afforded 20 (0.38 g, 55%) as an off-white solid; Rf 0.28 (10%
MeOH:DCM), mp 205−207 °C (lit.31 mp 209−210 °C). IR (cm−1)
3491, 3331, 3195, 2976, 2773, 1618, 1580, 1504, 1445, 1391, 1372,
1321, 1272, 1224, 1180, 1144. 1H NMR (300 MHz, DMSO-d6) δ 1.33
(6H, d, J = 6.2 Hz, 2 × CH3), 5.47 (1H, septet, J = 6.2 Hz, OCH), 6.17
(2H, s, NH2), 7.81 (1H, s, H-8), 12.39 (1H, br s, NH).
13C NMR (75
MHz, DMSO-d6) δ 22.3, 68.2, 160.1. LRMS (ES
+) m/z 194.15 [M +
H]+. Anal. Found: C, 49.48; H, 5.64; N, 35.71. C8H11N5O·0.1H2O
requires: C, 49.27; H, 5.79; N, 35.91
2-Amino-6-(2-methyl-1-propoxy)purine (21).31 2-Methyl-1-prop-
anol (1.31 mL, 14.2 mmol) was added to NaH (0.25 mg, 10.7 mmol)
in DMSO (10 mL), followed by addition of 17 (1.0 g, 3.6 mmol)
according to general procedure C, to afford the crude product.
Trituration of the residual yellow oil with petrol furnished a cream
solid. Purification by chromatography (silica; 5−10% MeOH:DCM)
gave 21 (0.42 g, 57%) as pale-yellow crystals; Rf 0.41 (10% MeOH/
DCM), mp 180−182 °C (lit.31 mp 89−92 °C). IR (cm−1) 3512, 3473,
3359, 2958, 2875, 1620, 1575, 1507, 1451, 1386, 1363, 1332, 1272,
1223, 1159, 1121. 1H NMR (300 MHz, DMSO-d6) δ 0.98 (6H, d, J =
6.7 Hz, 2 × CH3), 2.07 (1H, septet, J = 6.7 Hz, OCH2CH), 4.17 (2H,
d, J = 6.8 Hz, OCH2), 6.21 (2H, s, NH2), 7.82 (1H, s, H-8).
13C NMR
(75 MHz, DMSO-d6) δ 19.4, 27.8, 71.9, 160.1, 162.2. LRMS (ES
−) m/
z 206.81 [M − H]−.
2-Amino-6-(1-methylpropoxy)purine (22).31 Treatment of 2-
butanol (20 mL) with Na (0.68 g, 29.5 mmol), followed by addition
of 2-amino-6-chloropurine 9 (1.0 g, 5.9 mmol) was performed
according to general procedure B, to give a pale-yellow solid. H2O was
added, and the product was extracted into EtOAc (3 × 100 mL), dried
(MgSO4), and the solvent removed in vacuo to yield 22 (0.90 g, 74%)
as off-white crystals, Rf 0.3 (10% MeOH:DCM); mp 77 °C (dec)
(lit.31 mp 88−90 °C). IR (cm−1) 3322, 3190, 2971, 2936, 2876, 2772,
1616, 1575, 1504, 1451, 1393, 1375, 1326, 1273, 1222. 1H NMR (300
MHz, DMSO-d6) δ 0.91 (3H, t, J = 7.4 Hz, CH3CH2CHCH3), 1.29
(3H, d, J = 6.2 Hz, CH3CH2CHCH3), 1.57−1.79 (2H, m,
CH3CH2CHCH3), 5.27−5.38 (1H, m, CH3CH2CHCH3), 6.19 (2H,
s, NH2), 7.79 (1H, s, H-8).
13C NMR (75 MHz, DMSO-d6) δ 10.0,
19.8, 28.9, 72.7, 137.7, 160.1. LRMS (ES−) m/z 206.08 [M − H]−.
Anal. Found: C, 51.52; H, 6.43; N, 32.64. C9H13N5O·0.25H2O
requires: C, 51.05; H, 6.43; N, 33.08.
2-Amino-6-(prop-2-ynyloxy)purine (23).51 Treatment of propargyl
alcohol (0.83 mL, 14.2 mmol) with NaH (0.25 mg, 10.7 mmol) in
DMSO (10 mL), followed by addition of 17 (1.0 g, 3.6 mmol) was
performed according to general procedure C, affording the product 23
(0.54 g, 80%) as a beige solid, Rf 0.26 (10% MeOH:DCM); mp 181
°C (dec) (lit.51 mp 230 °C (dec)). IR (cm−1) 3319, 3190, 2777, 2126,
1651, 1621, 1589, 1510, 1460, 1438, 1400, 1339, 1277, 1221, 1184,
1142. 1H NMR (300 MHz, DMSO-d6) δ 3.58 (1H, t, J = 2.4 Hz,
OCH2CCH), 5.10 (2H, d, J = 2.4 Hz, OCH2CCH), 6.35 (2H, s,
NH2), 7.85 (1H, s, H-8).
13C NMR (75 MHz, DMSO-d6) δ 53.0, 78.0,
79.6, 113.7, 138.5, 155.7, 159.1, 159.9. LRMS (ES+) m/z 190.00 [M +
H]+.
2-Fluoro-6-ethoxypurine (24). Prepared following general proce-
dure D from 18 (1.0 g, 5.6 mmol) to give 24 as a white solid (0.22 g,
22%); Rf 0.39 (10% MeOH/DCM); mp 225−227 °C. IR (cm−1)
3117, 2997, 2740, 2669, 2506, 2363, 2339, 1836, 1760, 1605, 1487,
1425, 1373, 1343, 1281, 1219, 1151, 1111, 1038, 1007. 1H NMR (300
MHz, DMSO-d6) δ 1.41 (3H, t, J = 7.1 Hz, CH3), 4.57 (2H, q, J = 7.1
Hz, CH2), 8.39 (1H, s, H-8), 13.55 (1H, br s, NH).
13C NMR (75
MHz, DMSO-d6) δ 14.6 (CH3), 64.0 (CH2), 144.0 (C
8). LRMS (ES+)
m/z 183.1 [M + H]+. Anal. Found: C, 44.80; H, 3.67; N, 29.48.
C7H7N4OF·0.3H2O requires: C, 44.83; H, 4.08; N, 29.87.
2-Fluoro-6-n-propoxypurine (25). Synthesized in accordance with
general procedure D from 19 (1.0 g, 5.2 mmol) to yield 25 (0.58 g,
57%) as a white solid; Rf 0.18 (70% EtOAc:petrol); mp 197−199 °C.
IR (cm−1) 3105, 2973, 2944, 2886, 2741, 2680, 2523, 2362, 2338,
1772, 1607, 1422, 1368, 1347, 1269, 1213, 1149, 1038. 1H NMR (300
MHz, DMSO-d6) δ 1.00 (3H, t, J = 7.4 Hz, CH3) 1.82 (2H, tq, J = 7.1,
7.1 Hz, CH3CH2CH2O), 4.47 (2H, t, J = 6.7 Hz, CH3CH2CH2O),
8.39 (1H, s, H-8), 13.55 (1H, br s, NH). 13C NMR (75 MHz, DMSO-
d6) δ 10.5 (CH3), 22.0 (CH3CH2CH2O), 69.4 (O
6CH2), 144.0 (Ar-
C), 156.0 (C8), 158.8 (Ar-C). LRMS (ES+) m/z 154.0 [M − C3H7]+.
HRMS calcd for C8H9FN4O [M
+] 196.0760, found 196.0757.
2-Fluoro-6-isopropoxypurine (26). Synthesized by general prode-
cure D from 20 (0.30 g, 1.6 mmol) to yield 26 as a white solid (0.16 g,
53%); Rf 0.22 (70% EtOAc:petrol); mp 184 °C (dec). IR (cm
−1)
2990, 2536, 1605, 1472, 1424, 1371, 1275, 1034, 1017. 1H NMR (300
MHz, DMSO-d6) δ 1.40 (6H, d, J = 6.2 Hz, 2 × CH3), 5.49 (1H,
septet, J = 6.2 Hz, OCH), 8.37 (1H, s, H-8), 13.52 (1H, br s, NH). 13C
NMR (75 MHz, DMSO-d6) δ 22.0 (CH3), 71.5 (O
6CH), 162.2 (C8).
LRMS (ES+) m/z 154.0 [M − C3H7]+. HRMS calcd for C8H9FN4O
[M+] 196.0760, found 196.0760.
2-Fluoro-6-(2-methyl-1-propoxy)purine (27). From 21 (0.40 g, 1.9
mmol) in accordance with general procedure D to yield 27 (0.25 g,
62%) as a white solid; Rf 0.25 (70% EtOAc:petrol); mp 202−204 °C.
IR (cm−1) 3130, 3059, 2968, 2937, 2884, 2804, 2693, 2528, 1760,
1700, 1603, 1476, 1451, 1418, 1364, 1341, 1267, 1211, 1140, 1113,
1040. 1H NMR (300 MHz, DMSO-d6) δ 1.01 (6H, d, J = 6.7 Hz, 2 ×
CH3), 2.13 (1H, septet, J = 6.7 Hz, OCH2CH), 4.30 (2H, d, J = 6.7
Hz, OCH2), 8.40 (1H, s, H-8), 13.55 (1H, br s, NH).
13C NMR (75
MHz, DMSO-d6) δ 19.2 (CH3), 27.7 (O
6CH2CH), 73.7 (O
6CH2).
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LRMS (ES+) m/z 154.0 [M − C3H7]+. HRMS calcd for C9H11FN4O
[M+] 210.0917, found 210.0922.
2-Fluoro-6-(1-methylpropoxy)purine (28). Prepared according to
general procedure D from 22 (0.66 g, 3.2 mmol) as a white solid (0.29
g, 43%); Rf 0.21 (70% EtOAc:petrol); mp 187−189 °C. IR (cm−1)
2975, 2940, 1604, 1468, 1421, 1372, 1344, 1277, 1211, 1148, 1038. 1H
NMR (300 MHz, DMSO-d6) δ 0.93 (3H, t, J = 7.4 Hz,
CH3CH2CHCH3), 1.36 (3H, d, J = 6.2 Hz, CH3CH2CHCH3),
1.66−1.83 (2H, m, CH3CH2CHCH3), 5.29−5.37 (1H, m,
CH3CH2CHCH3), 8.37 (1H, s, H-8), 13.55 (1H, s, NH).
13C NMR
(75 MHz, DMSO-d 6) δ 9 .8 (CH3CH2CHCH3) , 19 .5
(CH3CH2CHCH3), 28.6 (CH3CH2CHCH3), 75.9 (CH3CH2CHCH3),
158.8 (C8). LRMS (ES−) m/z 209.1 [M − H]−. Anal. Found: C,
51.71; H, 5.27; N, 26.33. C9H11N4OF requires: C, 51.42; H, 5.27; N,
26.65.
2-Fluoro-6-(prop-2-ynyloxy)purine (29). Synthesized from 23
(0.28 g, 1.5 mmol) in accordance with general procedure D as a
pale-yellow solid (77 mg, 27%); Rf 0.18 (70% EtOAc:petrol); mp 201
°C (dec). IR (cm−1) 3261, 3123, 2970, 2864, 2803, 2363, 2336, 2140,
1651, 1607, 1460, 1379, 1341, 1275, 1217, 1142, 1107, 1048. 1H NMR
(300 MHz, DMSO-d6) δ 3.70 (1H, t, J = 2.4 Hz, OCH2CCH), 5.23
(2H, d, J = 2.2 Hz, OCH2CCH), 8.45 (1H, s, H-8).
13C NMR (75
MHz, DMSO-d6) δ 55.4 (O
6CH2CCH), 78.5 (O
6CH2CCH), 79.1
(O6CH2CCH), 162.2 (C
8). LRMS (ES+) m/z 192.0 [M+]. HRMS
calcd for C8H5FN4O [M
+] 192.0447, found 192.0448.
2-Sulfanilyl-6-ethoxypurine (30). Prepared from 24 (0.20 g, 1.1
mmol) following general procedure A. Purification by chromatography
(silica; 5−20% MeOH:DCM) afforded 30 (39 mg, 11%) as an off-
white solid; Rf 0.20 (10% MeOH:DCM); mp 265 °C (dec); UV λmax
(EtOH) 257, 241 nm. IR (cm−1) 3473, 3317, 3223, 2984, 2787, 2363,
2338, 1628, 1578, 1540, 1499, 1442, 1376, 1312, 1254, 1142, 1013. 1H
NMR (300 MHz, DMSO-d6) δ 1.43 (3H, t, J = 7.1 Hz, CH3), 4.59
(2H, q, J = 7.1 Hz, CH2), 7.16 (2H, s, NH2), 7.71 (2H, d, J = 8.9 Hz,
H-3′ and H-5′), 7.97 (2H, d, J = 8.9 Hz, H-2′ and H-6′), 8.08 (1H, s,
H-8), 9.76 (1H, s, NH), 12.69 (1H, s, NH). 13C NMR (75 MHz,
DMSO-d6) δ 14.9 (CH3), 62.6 (CH2), 117.6 (Ar-C), 126.8 (Ar-C),
155.1 (C8). LRMS (ES+) m/z 335.0 [M + H]+. HRMS calcd for
C13H14N6O3S [M
+] 334.0848, found 334.0835.
2-Sulfanilyl-6-propoxypurine (31). Prepared from 25 (0.25 g, 1.3
mmol) according to general procedure A. Purification by chromatog-
raphy (silica; 50−100% EtOAc:petrol followed by 0−10%
MeOH:DCM), afforded 31 (0.25 g, 56%) as a beige solid; Rf 0.10
(70% EtOAc:petrol); mp 207 °C (dec); UV λmax (EtOH) 310 nm. IR
(cm−1) 3251, 3115, 2971, 2934, 2878, 2361, 2340, 1700, 1596, 1580,
1528, 1498, 1453, 1389, 1321, 1306, 1243, 1146, 1094. 1H NMR (300
MHz, DMSO-d6) δ 1.03 (3H, t, J = 7.4 Hz, CH3) 1.85 (2H, tq, J = 6.9,
6.9 Hz, CH3CH2CH2O), 4.50 (2H, t, J = 6.8 Hz, CH3CH2CH2O),
7.17 (2H, s, NH2), 7.72 (2H, d, J = 8.8 Hz, H-2′ and H-6′), 7.97 (2H,
d, J = 8.8 Hz, H-3′ and H-5′), 8.09 (1H, s, H-8), 9.77 (1H, s, NH),
12.96 (1H, br s, NH). 13C NMR (75 MHz, DMSO-d6) δ 10.7 (CH3),
22.2 (CH3CH2CH2O), 68.2 (O
6CH2), 117.6 (CHCNH), 126.8
(CHCSO2NH2), 135.7 (Ar-CNH), 144.6 (CSO2NH2), 155.1 (C
8).
LRMS (ES+) m/z 349.8 [M + H]+. HRMS calcd for C14H16N6O3S
[M+] 348.1005, found 348.0994; Anal. Found: C 45.41; H 4.75; N
22.40. C14H16N6O3S·0.3CF3CO2H requires: C, 45.83; H, 4.29; N,
21.97.
2-Sulfanilyl-6-isopropoxypurine (32). Synthesized in accordance
with general procedure A from 26 (0.07 g, 0.4 mmol). Purification by
chromatography (silica; 50−100% EtOAc:petrol followed by 0−10%
MeOH:DCM), afforded 32 (38 mg, 31%) as a beige solid; Rf 0.03
(70% EtOAc:petrol); mp 177 °C (dec); UV λmax (EtOH) 307 nm. IR
(cm−1) 3472, 3312, 3210, 3117, 2982, 2793, 2691, 2643, 2362, 2342,
1715, 1685, 1617, 1597, 1578, 1538, 1500, 1440, 1381, 1306, 1255,
1140, 1117, 1096. 1H NMR (300 MHz, DMSO-d6) δ 1.42 (6H, d, J =
6.2 Hz, 2 × CH3), 5.59 (1H, septet, J = 6.2 Hz, OCH), 7.16 (2H, s,
NH2), 7.72 (2H, d, J = 8.8 Hz, H-2′ and H-6′), 7.96 (2H, d, J = 8.8 Hz,
2 × H-3′ and H-5′), 8.07 (1H, s, H-8), 9.74 (1H, s, NH), 12.91 (1H,
br s, NH). 13C NMR (75 MHz, DMSO-d6) δ 21.9 (CH3), 69.0
(O6CH), 117.1 (CHCNH), 126.5 (CHCSO2NH2), 135.2 (Ar-CNH),
144.3 (CSO2NH2), 154.7 (C
8). LRMS (ES+) m/z 349.8 [M + H]+.
HRMS calcd for C14H16N6O3S [M
+] 348.1005, found 348.1007.
2-Sulfanilyl-6-(2-methyl-1-propoxy)purine (33). Prepared follow-
ing general procedure A from 27 (0.12 g, 0.6 mmol). Purification by
chromatography (silica, 50−100% EtOAc:petrol followed by 0−10%
MeOH:DCM), afforded 33 (0.11 g, 53%) as a light-brown solid; Rf
0.21 (70% EtOAc:petrol); mp 133 °C (dec); UV λmax (EtOH) 308
nm. IR (cm−1) 3285, 3108, 2962, 2360, 2337, 1595, 1576, 1543, 1499,
1438, 1396, 1321, 1249, 1221, 1144, 1096, 1016. 1H NMR (300 MHz,
DMSO-d6) δ 1.03 (6H, d, J = 6.7 Hz, 2 × CH3), 2.16 (1H, septet, J =
6.7 Hz, OCH2CH), 4.33 (2H, d, J = 6.8 Hz, OCH2CH), 7.17 (2H, s,
NH2), 7.71 (2H, d, J = 8.9 Hz, H-2′ and H-6′), 7.97 (2H, d, J = 8.9 Hz,
H-3′ and H-5′), 8.09 (1H, s, H-8), 9.77 (1H, s, NH). 13C NMR (75
MHz, DMSO-d6) δ 19.4 (CH3), 27.9 (O
6CH2CH), 72.7 (O
6CH2),
117.6 (CHCNH), 126.8 (CHCSO2NH2), 135.7 (Ar-CNH), 144.6
(CSO2NH2), 155.1 (C
8). LRMS (ES+) m/z 363.8 [M + H]+. HRMS
calcd for C15H18N6O3S [M
+] 362.1161, found 362.1145.
(R/S)-6-(1-Methylpropoxy)-2-sulfanilylpurine (34). Synthesized
from 28 (0.1 g, 0.5 mmol) following general procedure A. Purification
by chromatography (silica; 50−100% EtOAc:petrol followed by 0−
10% MeOH:DCM), afforded 34 (41 mg, 24%) as a light-brown solid;
Rf 0.10 (70% EtOAc:petrol); mp 162 °C (dec); UV (EtOH) λmax 308
nm. IR (cm−1) 3649, 3317, 3219, 3106, 2972, 2938, 2874, 2363, 2340,
1701, 1596, 1579, 1528, 1498, 1453, 1389, 1306, 1243, 1145, 1094. 1H
NMR (300 MHz, DMSO-d6) δ 0.97 (3H, t, J = 7.4 Hz,
CH3CH2CHCH3), 1.39 (3H, d, J = 6.2 Hz, CH3CH2CHCH3),
1.68−1.87 (2H, m, CH3CH2CHCH3), 5.40−5.46 (1H, m,
CH3CH2CHCH3), 7.17 (2H, s, NH2), 7.72 (2H, d, J = 8.8 Hz, H-2′
and H-6′), 7.96 (2H, d, J = 8.9 Hz, H-3′ and H-5′), 8.13 (1H, s, H-8),
9.76 (1H, s, NH). 13C NMR (75 MHz, DMSO-d6) δ 10.0
(CH3CH2CHCH3), 19.7 (CH3CH2CHCH3), 28.8 (CH3CH2CHCH3),
74.2 (CH3CH2CHCH3), 117.6 (CHCNH), 126.8 (CHCSO2NH2),
135.8 (Ar-CNH), 144.6 (CSO2NH2), 155.2 (C
8). LRMS (ES+) m/z
363.8 [M + H]+. HRMS calcd for C15H18N6O3S [M
+] 362.1161, found
362.1166. Anal. Found: C, 48.32; H, 5.15; N, 22.08. C15H18N6O3S·
0.2CF3CO2H requires: C, 48.02; H, 4.76; N, 21.82.
2-Sulfanilyl-6-(prop-2-ynyloxy)purine (35). Synthesized in accord-
ance with general procedure A from 29 (0.045 g, 0.2 mmol).
Purification by chromatography (silica; 50−100% EtOAc:petrol
followed by 0−10% MeOH:DCM), yielded 35 (27 mg, 34%) as a
beige solid; Rf 0.1 (70% EtOAc:petrol); mp 161 °C (dec); UV
(EtOH) λmax 307 nm. IR (cm
−1) 3370, 3245, 2971, 2795, 2361, 2340,
1715, 1699, 1619, 1585, 1575, 1540, 1499, 1472, 1454, 1443, 1396,
1321, 1307, 1271, 1143, 1095. 1H NMR (300 MHz, DMSO-d6) δ 3.68
(1H, t, J = 2.3 Hz, OCH2CCH), 5.24 (2H, d, J = 2.3 Hz, OCH2CCH),
7.18 (2H, s, NH2), 7.72 (2H, d, J = 8.8 Hz, H-2′ and H-6′), 7.98 (2H,
d, J = 8.8 Hz, H-3′ and H-5′), 8.13 (1H, s, H-8), 9.87 (1H, s, NH). 13C
NMR (75 MHz, DMSO-d6) δ 53.6 (O
6CH2CCH), 78.0
(O6CH2CCH), 79.1 (O
6CH2CCH), 115.1 (Ar-C), 117.5 (CHCNH),
126.5 (CHCSO2NH2), 135.5 (Ar-CNH), 139.9 (C
2NH), 143.9
(CSO2NH2), 154.3 (C
8), 158.6 (Ar-C). LRMS (ES+) m/z 345.8 [M
+ H]+. HRMS calcd for C14H12N6O3S [M
+] 344.0692, found
344.0700.
6-Chloro-2-fluoro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine (36).
3,4-Dihydropyran (60 μL, 0.58 mmol) was added dropwise over 10
min to a vigorously stirred solution of 10 (0.10 g, 0.58 mmol) and
(rac)-camphorsulfonic acid (5 mg, 0.02 mmol) in EtOAc (50 mL) at
65 °C. The temperature was maintained at 65 °C for 18 h. The
resulting bright-yellow solution was neutralized to pH 7 by careful
addition of aqueous NH3 solution until a cloudy suspension persisted.
The crude mixture was washed with brine (2 × 30 mL) and the
aqueous phase was re-extracted with EtOAc (2 × 30 mL). The
combined organic extracts were dried (Na2SO4) and purified by
chromatography (silica; 30% EtOAc:petrol) to afford 36 as a pale-
yellow oil which became a white waxy solid on refrigeration (110 mg,
75%); mp 92−94 °C; UV λmax (EtOH) 269 nm. IR (cm−1) 3132,
2955, 2876, 1574. 1H NMR (500 MHz, DMSO-d6) δ 1.57−1.64 (2H,
m, CH2), 1.70−1.80 (1H, m, CH), 1.94−2.02 (2H, m, CH2), 2.23−
2.32 (1H, m, CH), 3.70−3.77 (1H, m, CH), 4.00−4.06 (1H, m, CH),
5.71 (1H, dd, J = 2.3, 10.9 Hz, NCH), 8.92 (1H, s, H-8). 13C NMR
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(125 MHz, DMSO-d6) δ 22.0 (N
9-CHCH2CH2), 24.3 (N
9-
CHOCH2CH2), 29.6 (N
9-CHCH2CH2), 67.7 (N
9-CHOCH2CH2),
81.7 (N9-CH), 130.1 (d, JCF = 4.8 Hz, Ar-C), 146.4 (d, JCF = 2.8 Hz,
Ar-C), 150.6 (d, JCF = 18.5 Hz, Ar-C), 153.2 (d, JCF = 17.6 Hz, Ar-C),
156.2 (d, JCF = 213.7 Hz, Ar-C
2). LRMS (ES+) m/z 257.2 [M + H]+.
2-Fluoro-9-(tetrahydro-2H-pyran-2-yl)-6-((triisopropylsilyl)-
ethynyl)-9H-purine (37). An oxygen-free solution of 36 (0.050 g, 1.95
mmol), bis(triphenylphosphine)palladium(II) chloride (41 mg, 3.0
mol %) and copper iodide (7 mg, 2.0 mol %) in THF (10 mL) was
degassed by bubbling nitrogen through the solution in a sealed vial for
5 min. Triisopropylsilylacetylene (0.50 mL, 2.2 mmol) and triethyl-
amine (0.70 mL, 4.9 mmol) were added to the mixture, which was
again degassed for 15 min. After stirring at room temperature for 18 h,
the black-brown suspension was filtered through Celite, eluting with
MeOH (3 × 20 mL). Purification by chromatography (silica; 10%
EtOAc:petrol) furnished 37 as a viscous yellow oil (78 mg, 99%); Rf
0.30 (10% EtOAc:petrol); UV λmax (EtOH) 303 nm. IR (cm
−1) 3433,
2946, 2866, 2706, 2361, 1703. 1H NMR (500 MHz, DMSO-d6) δ
1.12−1.25 (21H, m, Si(CH(CH3)2)3), 1.56−1.63 (2H, m, CH2),
1.71−1.80 (1H, m, CH), 1.94−2.03 (2H, m, CH2), 2.20−2.30 (1H, m,
CH), 3.70−3.78 (1H, m, CH), 4.01−4.07 (1H, m, CH), 5.70 (1H, dd,
J = 2.2, 10.8 Hz, NCH), 8.89 (1H, s, H-8). 13C NMR (125 MHz,
DMSO-d6) δ 10.5 (Si(CH(CH3)2)3), 18.4 (Si(CH(CH3)2)3), 22.0
(N9-CHCH2CH2), 24.4 (N
9-CHOCH2CH2), 29.7 (N
9-CHCH2CH2),
67.7 (N9-CHOCH2CH2), 81.4 (N
9-CH), 100.2 (CC), 102.8 (C
C), 133.9 (d, JCF = 4.6 Hz, Ar-C), 140.8 (d, JCF = 17.9 Hz, Ar-C),
146.6 (d, JCF = 2.8 Hz, Ar-C), 153.8 (d, JCF = 17.8 Hz, Ar-C), 157.4 (d,
JCF = 210.6 Hz, Ar-C
2). HRMS calcd for C21H32FN4OSi [M + H]
+
403.2324, found 403.2324.
2-Fluoro-6-((triisopropylsilyl)ethynyl)-9H-purine (38). The title
compound was prepared according to general procedure E from 37
(0.29 g, 0.72 mmol). Purification by chromatography (silica; 30%
EtOAc:petrol) gave 38 as a pale-yellow oil (22 mg, 96%); Rf 0.25 (30%
EtOAc:petrol); UV λmax (EtOH) 302 nm. IR (cm
−1) 2945, 2866,
2361, 2000, 1584. 1H NMR (500 MHz, DMSO-d6) δ 1.12−1.21 (21H,
m, Si(CH(CH3)2)3), 8.68 (1H, s, H-8), 13.89 (1H, br, NH).
13C NMR
(125 MHz, CDCl3) δ 11.1 (Si(CH(CH3)2)3), 18.5 (Si(CH(CH3)2)3),
99.5 (CC), 106.1 (CC), 131.2 (m, Ar-C), 141.6 (m, Ar-C), 145.3
(m, Ar-C), 156.6 (m, Ar-C), 158.6 (d, JCF = 217.4 Hz, Ar-C
2). HRMS
calcd for C16H24FN4Si [M + H]
+ 319.1749, found 319.1752.
6-(2-(Triisopropylsilyl)ethynyl)-N-phenyl-9H-purin-2-amine (39).
Prepared in accordance with general procedure A from 38 (0.455 g,
1.43 mmol). Purified by chromatography (silica; 5% MeOH:DCM) to
give the title compound as a yellow gum (0.39 g, 1.00 mmol, 70%); Rf
0.39 (5% MeOH:DCM); UV λmax (EtOH) 276 nm. IR (cm
−1) 3389,
2361, 2021. 1H NMR (500 MHz, CDCl3) δ 1.09−1.22 (21H, m,
Si(CH(CH3)2)3), 7.00−7.04 (1H, m, H-4′), 7.22 (1H, s, NH), 7.29
(2H, dd, J = 7.7, 8.1 Hz, H-3′ and H-5′), 7.46 (1H, s, H-8), 7.52 (2H,
dd, J = 1.7, 7.7 Hz, H-2′ and H-6′), 10.42 (1H, s, NH). 13C NMR (125
MHz, CDCl3) δ 11.3 (Si(CH(CH3)2)3), 18.7 (Si(CH(CH3)2)3), 100.8
(CC), 101.8 (CC), 120.7 (Ar-C), 123.7 (Ar-C), 129.4 (Ar-C),
139.2 (Ar-C), 141.0 (Ar-C), 142.6 (Ar-C), 153.4 (Ar-C), 156.5 (Ar-
C). LRMS (ES+) m/z 392.0 [M + H]+.
4-(6-( (Tr i isopropyls i ly l )ethynyl)-9H-purin-2-ylamino)-
benzenesulfonamide (40). Following general procedure A employing
38 (0.156 g, 0.49 mmol). Purification by reversed phase column
chromatography (C18 silica; 25−95% MeCN/water + 0.1%
HCOOH), afforded 40 as a yellow solid (70 mg, 30%); mp 163−
165 °C; UV λmax (EtOH) 361 nm. IR (cm
−1) 3327, 2944, 2867, 1569,
1531, 1368, 1149. 1H NMR (500 MHz, DMSO-d6) δ 1.15 (21H, m,
Si(CH(CH3)2)3), 7.17 (2H, s, SO2NH2), 7.70 (2H, d, J = 9.0 Hz, H-2′
and H-6′), 7.95 (2H, d, J = 9.0 Hz, H-3′ and H-5′), 8.33 (1H, s, H-8).
13C NMR (125 MHz, DMSO-d6) δ 10.6, 18.4, 90.6, 98.4, 117.1, 123.4,
126.5, 135.6, 144.0, 155.5, 165.0, 166.3, 166.5, 291.0, 286.5, 215.5.
LRMS (ES+) m/z 471.4 [M + H]+. HRMS calcd for C22H30N6O2SSi
[M + H]+ 471.1987, found 471.1942.
6-Ethynyl-N-phenyl-9H-purin-2-amine (41). Treatment of 39
(0.330 g, 0.84 mmol) according to general procedure F, followed by
purification by chromatography (silica; EtOAc), yielded 41 as a yellow
solid (201 mg, 100%); Rf 0.27 (100% EtOAc); mp 140−160 °C (dec);
UV λmax (EtOH) 243 nm. IR (cm
−1) 3414, 3111, 3072, 2920, 2110,
1704. 1H NMR (500 MHz, DMSO-d6) δ 4.86 (1H, s, CCH), 6.91−
6.96 (1H, m, H-4′), 7.29 (2H, dd, J = 7.6, 8.0 Hz, H-3′ and H-5′), 7.80
(2H, dd, J = 2.0, 8.0 Hz, H-2′ and H-6′), 8.30 (1H, s, H-8), 9.70 (1H,
s, NH), 13.17 (1H, br, NH). 13C NMR (125 MHz, DMSO-d6) δ 87.0
(CCH), 118.3 (Ar-C), 120.0 (Ar-C), 128.4 (Ar-C), 140.8 (Ar-C),
156.2 (Ar-C). HRMS calcd for C13H10N5 [M + H]
+ 236.0931, found
236.0934.
4-(6-Ethynyl-9H-purin-2-ylamino)benzenesulfonamide (42). De-
protection of 40 (0.050 g, 0.11 mmol) in accordance with general
procedure F, followed by purification by chromatography (silica; 10%
MeOH:DCM), afforded 42 as a beige solid (18 mg, 50%); mp 156−
158 °C. IR (cm−1) 3347, 3255, 2920, 2848, 2118, 1568, 1529, 1477,
1128. UV λmax (EtOH) 356, 292, 215 nm.
1H NMR (500 MHz,
DMSO-d6) δ 4.90 (1H, s, CCH), 7.16 (2H, s, SO2NH2), 7.17 (2H,
d, J = 9.0 Hz, H-2′ and H-6′), 7.93 (2H, d, J = 9.0 Hz, H-3′ and H-5′),
8.36 (1H, s, H-8). LRMS (ES+) m/z 315.1 [M + H]+. HRMS calcd for
C13H10N6O2S [M + H]
+ 315.0664, found 315.0687. Note: Insufficient
material for 13C NMR analysis.
6-Ethynyl-2-fluoro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine (43).
Deprotection of 37 (68 mg, 0.169 mmol) in accordance with general
procedure F, but using 1.2 mol equiv of TBAF, followed by
purification by chromatography (silica; 15−100% EtOAc:petrol),
afforded 43 as an off-white solid (41 mg, 100%); Rf 0.32 (50%
EtOAc:petrol). 1H NMR (500 MHz, CDCl3) δ 1.58−1.63 (1H, m,
CH), 1.63−1.78 (2H, m, CH2), 1.90−1.99 (1H, m, CH), 1.99−2.06
(1H, m, CH), 2.07−2.12 (1H, m, CH), 3.68−3.74 (1H, m, CH), 3.71
(1H, s, CCH), 4.09−4.14 (1H, m, CH), 5.65 (1H, dd, J = 2.6, 10.8
Hz, NCH), 8.26 (1H, s, H-8). LRMS (ES+) m/z 247.0 [M + H]+.
Note: Insufficient material for 13C NMR analysis.
6-Chloro-N-phenyl-9H-purin-2-amine (44). A mixture of N2-
phenylguanine trifluoroacetate (15) (2.00 g, 5.87 mmol) and N,N-
diethylaniline (1.9 mL, 11.73 mmol) in POCl3 (30 mL) was heated at
115 °C for 60 min. The resultant yellow solution was carefully added
dropwise to crushed ice−water with stirring, and the aqueous solution
was neutralized by cautious addition of aqueous NaOH solution (1.0
M). The aqueous mixture was extracted with EtOAc (2 × 20 mL), and
the combined organic extracts were dried (Na2SO4) and evaporated
under reduced pressure. Purification by chromatography (silica; 50%
EtOAc:petrol) gave 44 as a white powder (670 mg, 46%); mp 172−
174 °C; UV λmax (EtOH) 329, 272 nm. IR (cm
−1) 3399, 3289, 1627,
1601, 1571, 1540. 1H NMR (500 MHz, DMSO-d6) δ 6.89−6.92 (1H,
t, J = 7.5 Hz, H-4′), 7.23−7.26 (2H, dd, J = 7.4, 7.5 Hz, H-3′ and H-
5′), 7.71−7.73 (2H, d, J = 7.4 Hz, H-2′ and H-6′), 8.20 (1H, s, H-8),
9.81 (1H, br s, NH), 13.20 (1H, br s, NH). 13C NMR (125 MHz,
DMSO-d6) δ 118.6, 121.5, 128.5, 140.3, 142.4, 155.5. LRMS (ES
+) m/
z 246.1 [M + H]+.
6-Chloro-N-phenyl-9-(tetrahydro-2H-pyran-2-yl)-9H-purin-2-
amine (45). To a solution of 44 (0.2 g, 0.82 mmol) and CSA (0.01 g,
0.041 mmol) in EtOAc (25 mL) was added DHP (83 μL, 0.90 mmol),
and the mixture was heated at 75 °C for 17 h. After cooling, the pH
was adjusted to 8−9 with concentrated aqueous ammonia, and the
volatiles were removed in vacuo. Purification by chromatography
(silica; 1/2 to 2/1 EtOAc:petrol) furnished 45 as a waxy solid (194
mg, 72%); mp 194−196 °C; UV λmax (EtOH) 330, 275 nm. IR (cm−1)
3274, 3106, 2934, 2849, 1579, 1573, 1535. 1H NMR (500 MHz,
DMSO-d6) δ 1.38−1.39 (2H, m, CH2), 1.49−1.54 (1H, m, CH),
1.76−1.80 (2H, m, CH2), 2.09−2.17 (1H, m, CH), 3.43−3.48 (1H, m,
CH), 3.81−3.83 (1H, m, CH), 5.38−5.40 (1H, dd, J = 2.0, 11.0 Hz,
NCH), 6.74−6.77 (1H, t, J = 8.5 Hz, H-4′), 7.07−7.11 (2H, dd, J =
7.5, 8.5 Hz, H-3′ and H-5′), 7.56−7.58 (2H, d, J = 7.5 Hz, H-2′ and H-
6′), 8.26 (1H, s, H-8), 9.79 (1H, br s, NH), 13.21 (1H, br s, NH). 13C
NMR (125 MHz, DMSO-d6) δ 24.5, 29.4, 54.9, 67.7, 81.6, 118.7,
121.7, 124.7, 128.6, 140.1, 142.4, 149.3, 152.7, 155.3. LRMS (ES+) m/
z 329.7 [M + H]+.
N-Phenyl-6-(prop-1-yn-1-yl)-9-(tetrahydro-2H-pyran-2-yl)-9H-
purin-2-amine (46). A suspension of 45 (0.1 g, 0.30 mmol),
PdCl2(CH3CN)2 (0.8 mg, 0.003 mmol), dicyclohexylphosphino-
2′,4′,6′-triisopropylbiphenyl (4.3 mg, 0.009 mmol), and Cs2CO3
(0.26 g, 0.79 mmol) in acetonitrile (1 mL) was degassed for 10 min
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under a nitrogen atmosphere at room temperature. While degassing,
an excess of methylacetylene was condensed and added to the reaction
mixture via a cannula, and the reaction mixture was heated and stirred
at 40 °C for 2.5 h. After cooling to room temperature, water (5 mL)
was added and the mixture was extracted with EtOAc (3 × 15 mL).
The combined organic extracts were washed with brine (10 mL), dried
(MgSO4), and the solvent was evaporated under reduced pressure.
Purification by chromatography (silica; 30%−80% EtOAc:petrol) gave
46 as a colorless glassy compound (78 mg, 77%); Rf 0.27 (30%
EtOAc:petrol). 1H NMR (500 MHz, CDCl3) δ 1.62−1.85 (3H, m,
CH2 and CH), 2.06−2.15 (3H, m, CH2 and CH), 2.23 (3H, s, C
CCH3), 3.74−3.81 (1H, m, CH), 4.15−4.21 (1H, m, CH), 5.60−5.67
(1H, m, CH), 7.04 (1H, dd, J = 7.4, 7.3 Hz, H-4′), 7.34 (2H, dd, J =
8.5, 7.4 Hz, H-2′ and H-6′), 7.47 (1H, s, NH), 7.34 (2H, dd, J = 8.6,
0.9 Hz, H-3′ and H-5′), 8.03 (1H, s, H-8). LRMS (ES+) m/z 334.0 [M
+ H]+. Note: Insufficient material for 13C NMR analysis.
N-Phenyl-6-(phenylethynyl)-9-(tetrahydro-2H-pyran-2-yl)-9H-
purin-2-amine (47). To a degassed suspension of 45 (0.1 g, 0.30
mmol), PdCl2(CH3CN)2 (0.8 mg, 0.003 mmol), dicyclohexylphos-
phino-2′,4′,6′-triisopropylbiphenyl (4.3 mg, 0.009 mmol), and Cs2CO3
(0.26 g, 0.79 mmol) in anhydrous acetonitrile (1 mL) was added an
excess of phenylacetylene, and the mixture was heated at 80 °C for 2 h.
After cooling, water (5 mL) was added and the suspension was
extracted with EtOAc (3 × 15 mL). The combined organic extract was
washed with brine (10 mL) and dried (MgSO4), and the solvent was
removed in vacuo. Purification by chromatography (silica; 0−80%
EtOAc:petrol) gave 47 as a colorless glassy compound (94 mg, 78%);
Rf 0.53 (65% EtOAc:petrol).
1H NMR (500 MHz, CDCl3) δ 1.64−
1.88 (3H, m, CH2 and CH), 2.07−2.19 (3H, m, CH2 and CH), 3.74−
3.84 (1H, m, CH), 4.16−4.24 (1H, m, CH), 5.63−5.71 (1H, m, CH),
7.03−7.08 (1H, m, H-4′), 7.32−7.46 (5H, m, phenyl), 7.50 (1H, s,
NH), 7.70 (2H, d, J = 8.3 Hz, H-2′ and H-6′), 7.72−7.75 (2H, m, H-3′
and H-5′), 8.08 (1H, s, H-8). 13C NMR (125 MHz, CDCl3) δ 22.9,
25.0, 31.5, 68.8, 82.2, 84.1, 97.6, 118.9, 121.5, 122.5, 128.5, 129.0,
129.4, 130.0, 132.9, 139.8, 141.0, 142.3, 152.5, 156.2. LRMS (ES+) m/
z 396.4 [M + H]+.
N-Phenyl-6-(prop-1-yn-1-yl)-9H-purin-2-amine (48). Prepared in
accordance with general procedure E from 46 (0.061 g, 0.18 mmol).
Recrystallization from EtOAc-petrol gave 48 as a pale-yellow solid (18
mg, 40%); mp 155−158 °C (dec); UV λmax (EtOH) 272 nm. IR
(cm−1) 1529, 1577, 2236, 2919. 1H NMR (500 MHz, MeOD-d4) δ
2.12 (3H, s, CCCH3), 6.87 (1H, t, J = 7.3 Hz, H-4′), 7.18 (2H, t, J =
7.8 Hz, H-2′ and H-6′), 7.63 (2H, d, J = 7.9 Hz, H-3′ and H-5′), 8.04
(1H, s, H-8). 13C NMR (125 MHz, MeOD-d4) δ 4.3, 116.9, 119.2,
120.1, 122.9, 129.6, 163.2, 163.5. LRMS (ES+) m/z 250.1 [M + H]+.
HRMS calcd for C14H12N5 [M + H]
+ 250.1087, found 250.1085.
N-Phenyl-6-(phenylethynyl)-9H-purin-2-amine (49). Prepared in
accordance with general procedure E from 47 (0.055 g, 0.14 mmol).
Recrystallization from EtOAc−petrol gave 49 as a yellow solid (22 mg,
51%); mp 206−208 °C (dec); UV λmax (EtOH) 281 nm. IR (cm−1)
1532, 1574, 2208, 3226. 1H NMR (500 MHz, MeOD-d4) δ 6.79 (1H,
t, J = 7.3 Hz, H-4′), 7.11 (2H, dd, J = 7.8, 8.1 Hz, H-2′ and H-6′),
7.23−7.32 (3H, m, H-3′, H-5′ and Ar-H), 7.54−7.58 (4H, m, 4 ×
ArH), 8.02 (1H, s, H-8). 13C NMR (125 MHz, MeOD-d4) δ 97.3,
120.2, 122.8, 122.9, 129.6, 129.8, 131.2, 133.5, 141.8, 158.6. LRMS
(ES+) m/z 312.2 [M + H]+. HRMS calculated for C19H14N5 [M + H]
+
312.1244, found 312.1242.
6-Ethyl-2-fluoro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine (50). To
a solution of 43 (0.05 g, 0.20 mmol) and quinoline (20 μL) in EtOAc
(5 mL) was added Lindlar’s catalyst (10 mg, 20% w/w), and the
mixture was stirred for 2 h under an atmosphere of H2. The
suspension was filtered through Celite, eluting with methanol (30
mL), and volatiles were removed in vacuo. Purification by
chromatography (silica; 50% EtOAc:petrol) yielded 50 as a colorless
oil (50 mg, 99%); UV λmax (EtOH) 264 nm. IR (cm
−1) 2946, 2860,
2364, 2338, 1604. 1H NMR (500 MHz, DMSO-d6) δ 1.35 (3H, t, J =
7.5 Hz, CH3CH2), 1.59 (2H, m, CH2), 1.97 (1H, m, CH), 1.99 (2H, d,
J = 10.5 Hz, CH2), 2.50 (1H, m, CH), 3.01 (2H, q, J = 7.5 Hz,
CH3CH2), 3.73 (1H, m, CH), 4.04 (1H, d, J = 10.5 Hz, CH), 5.69
(1H, d, J = 10.5 Hz, CH), 8.74 (1H, s, H-8). 13C NMR (500 MHz,
DMSO-d6) δ 12.3, 22.7, 24.8, 26.5, 31.8, 68.9, 82.1, 142.1, 157.9,
159.6, 167.4, 167.5. LRMS (ES+) m/z 251.0 [M + H]+.
6-Ethyl-2-fluoro-9H-purine (51). Prepared in accordance with
general procedure E from 50 (0.18 g, 0.72 mmol). Purification by
chromatography (silica; 25% EtOAc:petrol) yielded 51 as a white solid
(0.117 g, 98%); mp 146−148 °C; UV λmax (EtOH) 269 nm. IR (cm−1)
1676, 1616, 1573. 1H NMR (400 MHz, DMSO-d6) δ 1.30 (3H, t, J =
7.5 Hz, CH3CH2), 3.00 (2H, q, J = 7.5 Hz, CH3CH2), 8.17 (1 H, s, H-
8). 13C NMR (125 MHz, DMSO-d6) δ 11.7, 25.9, 68.3, 116.0, 118.4,
146.4, 158.0 (d, JC−F = 206.0 Hz), 158.3 (d, JC−F = 31.5 Hz). LRMS
(ES+) m/z 167.7 [M + H]+.
4-(6-Ethyl-9H-purin-2-ylamino)benzenesulfonamide (52). Pre-
pared by general procedure A from 51 (0.081 g, 0.49 mmol),
following purification by chromatography (silica; 50% EtOAc:petrol),
as a white solid (33 mg, 21%); mp 291−293 °C; UV λmax (EtOH) 318,
287, 212 nm. IR (cm−1) 3377, 3060, 2852, 1388, 1158. 1H NMR (500
MHz, DMSO-d6) δ 1.35 (3H, t, J = 6.0 Hz, CH3CH2), 3.00 (2H, q, J =
6.0 Hz, CH3CH2), 7.14 (2H, br s, SO2NH2), 7.69 (2H, d, J = 7.5 Hz,
H-2′ and H-6′), 7.99 (2H, d, J = 7.5 Hz, H-3′ and H-5′), 8.17 (1H, s,
H-8), 9.89 (1H, br s, NH). 13C NMR (125 MHz, DMSO-d6) δ 12.3,
26.0, 117.0, 118.9, 125.4, 126.4, 135.2, 141.2, 144.4, 154.0, 155.5.
LRMS (ES+) m/z 318.6 [M + H]+. HRMS calcd for C13H14N6O2S [M
+ H]+ 319.097076, found 319.09788.
6-Cyclopropyl-2-fluoro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine
(53). The title compound was prepared from 36 (0.04 g, 0.27 mmol)
and potassium cyclopropyltrifluoroborate (50 mg, 0.19 mmol)
following general procedure G. Purification by chromatography (silica;
50% EtOAc:petrol) afforded 53 as a colorless oil (21 mg, 42%); UV
λmax (EtOH) 211, 325, 391 nm. IR (cm
−1) 2986. 1H NMR (400 MHz,
DMSO-d6) δ 1.25 (4H, d, J = 6.5 Hz, cyclopropyl 2 × CH2), 1.55 (2H,
m, CH2), 1.72 (1H, m, CH), 1.95 (2H, d, J = 10.5 Hz, CH2), 2.27 (1H,
m, CH), 2.67 (1H, m, cyclopropyl CH), 3.70 (1H, m, CH), 3.99 (1H,
d, J = 10.5 Hz, CH), 5.63 (1H, d, J = 10.5 Hz, CH), 8.70 (1H, s, H-8).
13C NMR (500 MHz, DMSO-d6) δ 11.9, 13.2, 22.2, 24.4, 29.7, 67.7,
81.3, 130.9, 144.1, 151.8, 157.6, 159.8, 176.9. LRMS (ES+) m/z 262.4
[M + H]+.
6-Cyclopropyl-2-fluoro-9H-purine (54). The title compound was
prepared from 53 (0.19 g, 0.72 mmol) employing general procedure E.
Purification by chromatography (silica; EtOAc) afforded 54 as a white
solid (0.12 g, 95%); mp 137−139 °C; UV λmax (EtOH) 323, 213 nm.
IR (cm−1) 3062. 1H NMR (400 MHz, DMSO-d6) δ 1.11 (4H, d, J =
6.5 Hz, cyclopropyl 2 × CH2), 2.51 (1H, m, cyclopropyl CH), 8.40
(1H, s, H-8). 13C NMR (400 MHz, DMSO-d6) δ 11.6, 13.1, 131.2,
144.2, 151.8, 157.6, 159.8. LRMS (ES+) m/z 179.0 [M + H]+.
4-(6-Cyclopropyl-9H-purin-2-ylamino)benzenesulfonamide (55).
Synthesized following general procedure A from 54 (0.086 g, 0.49
mmol). Purification by chromatography (silica; EtOAc) afforded 55 as
a pale-yellow solid (24 mg, 15%); mp 291−293 °C; UV λmax (EtOH)
315.5, 289, 213 nm. IR (cm−1) 3389, 3062, 2921, 2851, 1727, 1604,
1579, 1531, 1379, 1149. 1H NMR (500 MHz, DMSO-d6) δ 1.23 (4H,
d, J = 6.5 Hz, cyclopropyl 2 × CH2), 1.35 (1H, m, cyclopropyl CH),
7.18 (2H, br s, SO2NH2), 7.74 (2H, d, J = 8.0 Hz, H-2′ and H-6′), 7.99
(2H, d, J = 8.0 Hz, H-3′ and H-5′), 8.22 (1H, s, H-8), 9.75 (1H, br s,
NH). 13C NMR (125 MHz, DMSO-d6) δ 10.5, 13.0, 117.1, 126.4,
126.6, 141.1, 144.4, 151.8, 155.5, 162.9. LRMS (ES+) m/z 331.1 [M +
H]+. HRMS calcd for C14H15N6O2S [M + H]
+ 331.0977, found
331.0980.
2-Fluoro-6-phenyl-9-(tetrahydro-2H-pyran-2-yl)-9H-purine (56).
Synthesized in accordance with general procedure G from 36 (0.20
g, 0.78 mmol) and phenylboronic acid (0.133 g, 1.09 mmol).
Purification by chromatography (silica; 20% EtOAc:petrol) gave 56 as
a white solid (0.30 g, 95%); mp 138−140 °C; UV λmax (EtOH) 306,
269, 203 nm. IR (cm−1) 3117, 2956, 2858, 1586. 1H NMR (300 MHz,
DMSO-d6) δ 1.60 (2H, m, CH2), 1.76 (1H, m, CH), 2.02 (2H, m,
CH2), 2.29 (1H, s, CH), 3.77 (1H, t, J = 12.0 Hz, CH), 4.04 (1H, d, J
= 12.0 Hz, CH), 5.74 (1H, d, J = 12.0 Hz, CH), 7.64, (3H, m, H-3″,
H-4″ and H-5″), 8.79 (2H, dd, J = 3.0, 7.5 Hz, H-2″ and H-6″), 8.25
(1H, s, H-8). 13C NMR (125 MHz, DMSO-d6) δ 22.2, 24.4, 29.7, 67.7,
81.3, 128.9, 129.3, 129.5, 132.0, 134.0, 145.4, 154.3 (d, JC−F = 17.5
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Hz), 155.5 (d, JC−F = 144.0 Hz), 157.0, 158.7. LRMS (ES
+) m/z 299.3
[M + H]+.
2-Fluoro-6-(3-methoxyphenyl)-9-(tetrahydro-2H-pyran-2-yl)-9H-
purine (57). Prepared according to general procedure G from 36 (0.20
g, 0.78 mmol) and 4-methoxyphenylboronic acid (0.16 g, 1.09 mmol).
Purification by chromatography (silica; 30% EtOAc:petrol) gave 57 as
a white solid (0.29 g, 80%); mp 133−135 °C; UV λmax (EtOH) 306,
271, 204 nm. IR (cm−1) 3089, 2938, 2857, 1761, 1586, 1516. 1H NMR
(300 MHz, DMSO-d6) δ 1.60 (2H, m, CH2), 1.76 (1H, m, CH), 2.02
(2H, m, CH2), 2.29 (1H, s, CH), 3.77 (1H, t, J = 12.0 Hz, CH), 3.89
(3H, s, OCH3), 4.04 (1H, d, J = 12.0 Hz, CH), 5.74 (1H, d, J = 12.0
Hz, CH), 7.18 (1H, m, H-2″), 7.50−7.55 (1H, m, H-5″), 8.45−8.49
(2H, m, H-4″, H-6″), 8.78 (1H, s, H-8). 13C NMR (125 MHz,
DMSO-d6) δ 22.2, 24.4, 29.7, 55.3, 67.7, 81.3, 114.4, 117.9, 122.0,
129.4, 130.0, 135.3, 145.4, 154.3 (d, JC−F = 17.5 Hz), 155.0 (d, JC−F =
160.0 Hz), 156.9, 158.6, 159.4. LRMS (ES+) m/z 334.2 [M + H]+.
2-Fluoro-6-(4-methoxyphenyl)-9-(tetrahydro-2H-pyran-2-yl)-9H-
purine (58). Synthesized in accordance with general procedure G from
36 (0.20 g, 0.78 mmol) and 4-methoxyphenylboronic acid (0.16 g,
1.09 mmol). Purification by chromatography (silica; 30% EtOAc:pe-
trol) afforded 58 as a white solid (0.35 g, 98%); mp 131−133 °C; UV
λmax (EtOH) 306, 271, 204 nm. IR (cm
−1) 3089, 2938, 2857, 1761,
1586, 1516. 1H NMR (300 MHz, DMSO-d6) δ 1.60 (2H, m, CH2),
1.76 (1H, m, CH), 2.02 (2H, m, CH2), 2.29 (1H, s, CH), 3.77 (1H, t, J
= 12.0 Hz, CH), 3.88 (3H, s, OCH3), 4.04 (1H, d, J = 12.0 Hz, CH),
5.74 (1H, d, J = 12.0 Hz, CH), 7.15−7.18 (2H, d, J = 9.0 Hz, H-3″ and
H-5″), 8.79−8.81 (2H, d, J = 9.0 Hz, H-2″ and H-6″), 8.85 (1H, s, H-
8). 13C NMR (125 MHz, DMSO-d6) δ 22.2, 24.4, 29.7, 55.5, 67.7,
81.2, 114.3, 126.5, 128.5, 131.5, 144.7, 153.9 (d, JC−F = 17.5 Hz), 155.2
(d, JC−F = 160.0 Hz), 157.0, 158.7, 162.4. LRMS (ES
+) m/z 329.2 [M
+ H]+.
6-(3-Biphenyl)-2-fluoro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine
(59). Prepared following general procedure G from 36 (0.20 g, 0.78
mmol) and 3-biphenylboronic acid (0.22 g, 1.09 mmol). Purification
by chromatography (silica; 20% EtOAc:petrol) furnished 59 as a pale-
yellow solid (0.33 g, 80%); mp 221−223 °C; UV λmax (EtOH) 346,
274 nm. IR (cm−1) 2992, 2844, 2601, 1589. 1H NMR (300 MHz,
DMSO-d6) δ 1.60 (2H, m, CH2), 1.76 (1H, m, CH), 2.02 (2H, m,
CH2), 2.29 (1H, s, CH), 3.77 (1H, t, J = 12.0 Hz, CH), 4.04 (1H, d, J
= 12.0 Hz, CH), 5.79 (1H, d, J = 12.0 Hz, CH), 7.45 (1H, d, J = 7.0
Hz, H-6″), 7.56 (1H, dd, J = 7.0, 7.1 Hz, H-5″), 7.78 (5H, m, Ph), 8.40
(1H, s, H-2″), 8.84 (1H, d, J = 7.1 Hz, H-4″), 9.18 (1H, s, H-8). 13C
NMR (125 MHz, DMSO-d6) δ 22.2, 24.4, 29.7, 67.7, 81.3, 126.8,
127.8, 127.9, 128.4, 129.1, 129.5, 129.6, 130.3, 134.7, 139.6, 140.8,
145.6, 154.4 (d, JC−F = 17.5 Hz), 155.2 (d, JC−F = 116.0 Hz), 157.0,
158.5. LRMS (ES+) m/z 375.1 [M + H]+.
2-Fluoro-6-(3-piperonyl)-9-(tetrahydro-2H-pyran-2-yl)-9H-purine
(60). Synthesized in accordance with general procedure G from 36
(0.20 g, 0.78 mmol) and 3,4-(methylenedioxy)phenylboronic acid
(0.18 g, 1.09 mmol). Purification by chromatography (silica; 30%
EtOAc:petrol) yielded 60 as a white solid (0.21 g, 56%); mp 151−153
°C; UV λmax (EtOH) 351, 284 nm. IR (cm
−1) 3011, 2917, 1721, 1616,
1511. 1H NMR (300 MHz, DMSO-d6) δ 1.60 (2H, m, CH2), 1.76
(1H, m, CH), 2.02 (2H, m, CH2), 2.29 (1H, s, CH), 3.73 (1H, t, J =
12.0 Hz, CH), 4.04 (1H, d, J = 12.0 Hz, CH), 5.73 (1H, d, J = 12.0 Hz,
CH), 6.17 (2H, s, OCH2O), 7.14−7.17 (1H, d, J = 8.0 Hz, H-5″), 8.28
(1H, s, H-2″), 8.48−8.51 (1H, d, J = 8.0 Hz, H-6″), 8.82 (1H, s, H-8).
13C NMR (125 MHz, DMSO-d6) δ 22.2, 24.4, 29.7, 67.7, 81.2, 101.9,
108.6, 125.4, 128.0, 128.6, 144.9, 147.8, 150.6, 154.1, 154.8, 156.9,
158.7. LRMS (ES+) m/z 343.1 [M + H]+.
6-(4-Dibenzofuryl)-2-fluoro-9-(tetrahydro-2H-pyran-2-yl)-9H-pu-
rine (61). Prepared according to general procedure G from 36 (0.20 g,
0.78 mmol) and 4-dibenzofuranboronic acid (0.23 g, 1.09 mmol).
Purification by chromatography (silica; 30% EtOAc:petrol) yielded 61
as a cream solid (0.39 g, 92%); mp 168−170 °C; UV λmax (EtOH)
398, 256, 202 nm. IR (cm−1) 3092, 2589, 1579. 1H NMR (300 MHz,
DMSO-d6) δ 1.60 (2H, m, CH2), 1.76 (1H, m, CH), 2.02 (2H, m,
CH2), 2.29 (1H, s, CH), 3.77 (1H, t, J = 12 Hz, CH), 4.04 (1H, d, J =
12.0 Hz, CH), 5.79 (1H, d, J = 12.0 Hz, CH), 7.45−7.47 (1H, dd, J =
7.0, 7.1 Hz, H-2″), 7.52−7.62 (1H, dd, J = 8.0, 8.1 Hz, H-7″), 7.61−
7.71 (1H, dd, J = 8.0, 8.1 Hz, H-8″), 7.76−7.79 (1H, d, J = 8.0 Hz, H-
9″), 8.25−8.27 (1H, d, J = 7.1 Hz, H-3″), 8.42−8.44 (1H, d, J = 8.0
Hz, H-6″), 8.55−8.58 (1H, d, J = 7.5 Hz, H-1″), 8.93 (1H, s, H-8). 13C
NMR (125 MHz, DMSO-d6) δ 22.2, 24.5, 29.7, 67.8, 68.3, 81.4, 111.9,
119.3, 121.3, 122.9, 123.1, 123.4, 124.3, 125.2, 128.1, 130.1, 145.6,
153.1, 154.7 (d, JC−F = 18.0 Hz), 155.7 (d, JC−F = 160.0 Hz), 156.9,
158.5. LRMS (ES+) m/z 389.4 [M + H]+.
2-Fluoro-6-(1-thianthrenyl)-9-(tetrahydro-2H-pyran-2-yl)-9H-pu-
rine (62). Prepared in accordance with general procedure G from 36
(0.20 g, 0.78 mmol) and 1-thianthreneboronic acid (0.28 g, 1.09
mmol). Purification by chromatography (silica; 30% EtOAc:petrol)
afforded 62 as an orange solid (0.43 g, 90%); mp 164−166 °C; UV
λmax (EtOH) 396, 224 nm. IR (cm
−1) 3092, 2814, 2589, 1611, 1497.
1H NMR (300 MHz, DMSO-d6) δ 1.60 (2H, m, CH2), 1.76 (1H, m,
CH), 2.02 (2H, m, CH2), 2.29 (1H, s, CH), 3.77 (1H, t, J = 12.0 Hz,
CH), 4.04 (1H, d, J = 12.0 Hz, CH), 5.79 (1H, d, J = 12.0 Hz, CH),
7.21−7.30 (1H, dd, J = 7.4, 7.5 Hz, H-3″), 7.31−7.39 (1H, dd, J = 7.5,
7.6 Hz, H-7″), 7.37−7.45 (1H, d, J = 7.5 Hz, H-9″), 7.51−7.58 (1H,
dd, J = 7.5, 7.6 Hz, H-8″), 7.59−7.65 (1H, d, J = 7.5 Hz, H-6″), 7.79
(1H, d, J = 7.4 Hz, H-2″), 7.89 (1H, d, J = 7.5 Hz, H-4″), 8.93 (1H, s,
H-8). 13C NMR (125 MHz, DMSO-d6) δ 22.2, 24.4, 29.5, 67.7, 68.3,
81.5 127.5, 128.2, 128.5, 128.7, 128.9, 130.6, 130.9, 131.4, 134.5, 134.7,
135.1, 135.5, 136.4, 146.2, 153.8 (d, JC−F = 17.5 Hz), 156.2, 155.0 (d,
JC−F = 150.0 Hz), 157.2. LRMS (ES
+) m/z 437.2 [M + H]+.
2-Fluoro-6-phenyl-9H-purine (63). Prepared from 56 (0.22 g, 0.72
mmol) following general procedure E. Repeated trituration of the
precipitated solid with water gave 63 (0.14 g, 90%); mp 273−275 °C;
UV λmax (EtOH) 349 nm. IR (cm
−1) 2820, 1599, 1560. 1H NMR (300
MHz, DMSO-d6) δ 7.62 (3H, m, H-3″, H-4″ and H-5″), 8.68 (1 H, s,
H-8), 8.81 (2H, m, H-2″ and H-6″). 13C NMR (125 MHz, DMSO-d6)
δ 128.8, 129.4, 131.7, 134.4, 145.7, 154.4, 156.0, 157.1, 158.7. LRMS
(ES+) m/z 214.6 [M + H]+.
2-Fluoro-6-(3-methoxyphenyl)-9H-purine (64). Deprotection of
57 (0.24 g, 0.72 mmol) in accordance with general procedure E
afforded the title compound 64 (0.17 g, 98%) following repeated
trituration of the precipitated solid with water; mp 237−238 °C; UV
λmax (EtOH) 251 nm. IR (cm
−1) 2837, 1864, 1587, 1565. 1H NMR
(300 MHz, DMSO-d6) δ 3.89 (3H, s, OCH3), 7.18 (1 H, s, H-2″),
7.50−7.55 (1H, m, H-5″), 8.37 (1H, s, H-8), 8.45−8.49 (2H, m, H-4″,
H-6″). 13C NMR (125 MHz, DMSO-d6) δ 55.3, 114.2, 117.6, 121.8,
130.0, 135.7, 146.3, 154.3, 157.2, 158.6, 159.4. LRMS (ES+) m/z 245.5
[M + H]+.
2-Fluoro-6-(4-methoxyphenyl)-9H-purine (65). Synthesized in
accordance with general procedure E from 58 (0.24 g, 0.72 mmol).
Trituration of the precipitated solid with water furnished 65 as a pale-
yellow solid (0.17 g, 95%); mp 212−214 °C; UV λmax (EtOH) 204
nm. IR (cm−1) 2845, 1586. 1H NMR (300 MHz, DMSO-d6) δ 3.88
(3H, s, OCH3), 7.15−7.18 (2H, d, J = 9.0 Hz, H-3″ and H-5″), 8.60
(1H, s, H-8), 8.79−8.81 (2H, d, J = 9.0 Hz, H-2″ and H-6″). 13C
NMR (500 MHz, DMSO-d6) δ 55.4, 114.1, 114.3, 126.8, 127.5, 131.3,
145.3, 157.1, 158.8, 162.2. LRMS (ES+) m/z 245.2 [M + H]+.
6-(Biphenyl-3-yl)-2-fluoro-9H-purine (66). The title compound was
prepared according to general procedure E from 59 (0.27 g, 0.72
mmol). Repeated washing of the precipitated solid with water gave 66
(0.20 g, 97%); mp 245−247 °C; UV λmax (EtOH) 349 nm. IR (cm−1)
1607, 1568. 1H NMR (300 MHz, DMSO-d6) δ 7.43−7.45 (1H, d, J =
7.0 Hz, H-6″), 7.54−7.58 (1H, dd, J = 6.9, 7.0 Hz, H-5″), 7.74−7.81
(5H, m, Ph), 8.40 (1H, s, H-2″), 8.80−8.85 (1H, d, J = 6.9 Hz, H-4″),
8.91 (1H, s, H-8). 13C NMR (125 MHz, DMSO-d6) δ 126.8, 127.7,
127.9, 128.2, 129.1, 129.5, 130.0, 135.0, 139.7, 140.7, 146.1 (m, JC−F),
157.1, 158.7. LRMS (ES+) m/z 291.1 [M + H]+.
6-(Benzo[d][1,3]dioxol-5-yl)-2-fluoro-9H-purine (67). Deprotec-
tion of 60 (0.25 g, 0.72 mmol) was achieved following general
procedure E. Trituration of the white solid that precipitated yielded 67
(0.16 g, 87%); mp 165−167 °C; UV λmax (EtOH) 351, 292 nm. IR
(cm−1) 2955, 2859, 1601, 1570, 1504. 1H NMR (300 MHz, DMSO-
d6) δ 6.17 (2H, s, OCH2O), 7.18−7.18 (1H, d, J = 8.0 Hz, H-5″), 8.28
(1H, s, H-2″), 8.48−8.51 (1H, d, J = 8.0 Hz, H-6″), 8.63 (1H, s, H-8).
13C NMR (125 MHz, DMSO-d6) δ 101.9, 108.6, 125.1, 128.4, 145.3,
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147.8, 150.3, 153.9 (d, JC−F = 17.5 Hz), 156.0 (d, JC−F = 150.0 Hz),
157.0, 158.6. LRMS (ES+) m/z 259.2 [M + H]+.
6-(4-Dibenzofuranyl)-2-fluoro-9H-purine (68). The title com-
pound was prepared in accordance with general procedure E from
61 (0.28 g, 0.72 mmol) and purified by repeated washing with water to
afford 68 as an off-white solid (0.20 g, 94%); mp 266−268 °C; UV
λmax (EtOH) 250 nm. IR (cm
−1) 3020, 2923, 2832, 1867, 1611, 1568.
1H NMR (300 MHz, DMSO-d6) δ 7.45−7.48 (1H, dd, J = 7.0, 7.1 Hz,
H-2″), 7.55−7.63 (1H, dd, J = 7.9, 8.0 Hz, H-7″), 7.61−7.68 (1H, dd,
J = 7.9, 8.0 Hz, H-8″), 7.76−7.79 (1H, d, J = 8.0 Hz, H-9″), 8.26−8.29
(1H, d, J = 7.1 Hz, H-3″), 8.43−8.45 (1H, d, J = 8.0 Hz, H-6″), 8.55−
8.58 (1H, d, J = 7.0 Hz, H-1″), 8.78 (1H, s, H-8). 13C NMR (500
MHz, DMSO-d6) δ 112.1, 121.3, 123.0, 123.5, 124.0, 125.0, 128.0,
130.0, 155.7. LRMS (ES+) m/z 305.1 [M + H]+.
2-Fluoro-6-(thianthren-1-yl)-9H-purine (69). Synthesized follow-
ing general procedure E from 62 (0.32 g, 0.72 mmol) and purified by
repeated trituration with water to give 69 (0.36 g, 93%); mp 166−168
°C; UV λmax (EtOH) 250 nm. IR (cm
−1) 3068, 2817, 2572, 1609,
1511. 1H NMR (300 MHz, DMSO-d6) δ 7.21−7.29 (1H, dd, J = 7.4,
7.5 Hz, H-3″), 7.31−7.38 (1H, dd, J = 7.5, 7.6 Hz, H-7″), 7.39−7.46
(1H, d, J = 7.5 Hz, H-9″), 7.49−7.55 (1H, dd, J = 7.5, 7.6 Hz, H-8″),
7.58−7.64 (1H, d, J = 7.5 Hz, H-6″), 7.79 (1H, d, J = 7.5 Hz, H-2″),
7.88−7.91 (1H, d, J = 7.4 Hz, H-4″), 8.31 (1H, s, H-8). 13C NMR
(125 MHz, DMSO-d6) δ 124.6, 127.5, 128.2, 128.4, 128.7, 128.9,
130.5, 131.1, 134.7, 134.9, 156.4, 159.9, 160.5. LRMS (ES+) m/z 353.1
[M + H]+.
4-(6-Phenyl-9H-purin-2-ylamino)benzenesulfonamide (70). The
title compound was synthesized according to general procedure A
from 63 (0.10 g, 0.49 mmol). Purified by chromatography (silica; 50%
EtOAc:petrol) to give 70 as a white solid (80 mg, 45%); mp 153−155
°C; UV λmax (EtOH) 349, 294 nm. IR (cm
−1) 3313, 2922, 2852, 1706,
1589, 1569, 1524, 1373, 1144. 1H NMR (300 MHz, DMSO-d6) δ 7.17
(2 H, br s, SO2NH2), 7.60 (3H, m, H-3″, H-4″ and H-5″), 7.75−7.78
(2H, d, J = 8.5 Hz, H-2′ and H-6′), 8.03−8.06 (2H, d, J = 8.5 Hz, H-3′
and H-5′) 8.37 (1H, s, H-8), 8.94 (2H, m, H-2″ and H-6″), 9.91 (1H,
br s, NH). 13C NMR (125 MHz, DMSO-d6) δ 117.2, 125.4, 126.5,
128.5, 129.3, 130.8, 135.4, 135.8, 142.6, 144.3, 153.0, 154.6, 155.3.
LRMS (ES+) m/z 367.2 [M + H]+. HRMS calcd for C17H14N6O2S [M
+ H]+ 367.0972, found 367.0974.
4 - ( 6 - ( 3 - M e t h o x y p h e n y l ) - 9 H - p u r i n - 2 - y l a m i n o ) -
benzenesulfonamide (71). Prepared in accordance with general
procedure A from 64 (0.12 g, 0.49 mmol) and purified by
chromatography (silica; 50% EtOAc:petrol) to furnish 71 as a white
solid (64 mg, 33%); mp 288−290 °C; UV λmax (EtOH) 294 nm. IR
(cm−1) 3377, 3097, 3020, 2838, 1729, 1597, 1566, 1531, 1365, 1145.
1H NMR (300 MHz, DMSO-d6) δ 3.89 (3H, s, OCH3), 7.17 (2H, s,
SO2NH2), 7.18 (1H, s, H-2″), 7.50−7.55 (1H, m, H-5″), 7.74−7.77
(2H, d, J = 8.0 Hz, H-2′ and H-6′), 8.03−8.06 (2H, d, J = 8.0 Hz, H-3′
and H-5′), 8.37 (1H, s, H-8), 8.45−8.49 (2H, m, H-4″ and H-6″). 13C
NMR (125 MHz, DMSO-d6) δ 55.2, 114.2, 116.6, 117.2, 121.8, 126.5,
129.6, 135.4, 137.1, 144.3, 146.3, 155.2, 115.6, 159.3. LRMS (ES+) m/
z 397.3 [M + H]+. HRMS calcd for C18H16N6O3S [M + H]
+ 397.1077,
found 397.1071.
4 - ( 6 - ( 4 - M e t h o x y p h e n y l ) - 9 H - p u r i n - 2 - y l a m i n o ) -
benzenesulfonamide (72). Synthesed following general procedure A
from 65 (0.12 g, 0.49 mmol) and isolated by chromatography (silica;
50% EtOAc:petrol) to yield 72 as a white solid (90 mg, 46%); mp
172−174 °C; UV λmax (EtOH) 301, 203 nm. IR (cm−1) 3322, 2133,
2005, 1594, 1533, 1514, 1352, 1147. 1H NMR (300 MHz, DMSO-d6)
δ 3.88 (3H, s, OCH3), 7.17 (2H, br s, SO2NH2), 7.18 (2H, d, J = 8.5
Hz, H-3″ and H-5″), 7.74−7.77 (2H, d, J = 8.0 Hz, H-2′ and H-6′),
8.02−8.05 (2H, d, J = 8.0 Hz, H-3′ and H-5′), 8.32 (1H, s, H-8),
8.84−8.87 (2H, d, J = 8.5 Hz, H-2″ and H-6″). 13C NMR (125 MHz,
DMSO-d6) δ 55.4, 114.0, 117.2, 124.8, 126.5, 128.2, 131.0, 135.3,
142.0, 144.4, 152.8, 154.3, 155.3, 161.5. LRMS (ES+) m/z 397.3 [M +
H]+. HRMS calcd for C18H16N6O3S [M + H]
+ 397.1077, found
397.1071.
4 - ( ( 6 - ( [ 1 , 1 ′ - B i pheny l ] - 3 - y l ) - 9H -pu r i n - 2 - y l ) am ino ) -
benzenesulfonamide (73). Treatment of 66 (0.14 g, 0.49 mmol) in
accordance with general procedure A with purification by chromatog-
raphy (silica; EtOAc) afforded 73 as a white solid (46 mg, 21%); mp
153−155 °C; UV λmax (EtOH) 349, 294 nm. IR (cm−1) 3313, 2922,
2852, 1706, 1589, 1569, 1524, 1373, 1144. 1H NMR (300 MHz,
DMSO-d6) δ 7.18 (1H, br s, SO2NH2), 7.39−7.50 (1H, d, J = 7.0 Hz,
H-6″), 7.50−7.62 (1H, dd, J = 7.0, 7.1 Hz, H-5″), 7.66−7.83 (5H, m,
Ph), 7.83−7.93 (2H, d, J = 8.0 Hz, H-2′ and H-6′), 8.00−8.13 (2H, d,
J = 8.0 Hz, H-3′ and H-5′), 8.35−8.40 (1H, s, H-2″), 8.78−8.93 (1H,
d, J = 7.1 Hz, H-4″), 9.18 (1H, s, H-8), 10.00 (1H, br s, NH). LRMS
(ES+) m/z 367.2 [M + H]+. HRMS calcd for C23H18N6O2S [M + H]
+
367.0972, found 367.0974. HPLC: >96%, XSELECT column,
retention time 7.48 min, reverse phase, H2O/MeCN/HCOOH
gradient run, 1 mL min−1.
4-(6- (Benzo[d] [1 ,3 ]d ioxol-5-y l ) -9H-pur in-2-y lamino)-
benzenesulfonamide (74). The title compound was prepared
following general procedure A from 67 (0.13 g, 0.49 mmol).
Purification by chromatography (silica; EtOAc) gave 74 as a pale-
yellow solid (30 mg, 15%); mp 284−286 °C; UV λmax (EtOH) 352,
295 nm. IR (cm−1) 3174, 1573, 1526, 1408, 1350, 1153. 1H NMR
(300 MHz, DMSO-d6) δ 6.14 (2H, s, OCH2O), 7.15 (2H, s,
SO2NH2), 7.73−7.75 (2H, d, J = 8.0, H-2′ and H-6′), 7.98−8.01 (2H,
d, J = 8.0 Hz, H-3′ and H-5′), 8.31 (1H, s, H-8), 8.37 (1H, s, H-2″),
8.55 (2H, m, H-5″ and H-6″), 9.89 (1H, br s, NH). 13C NMR (125
MHz, DMSO-d6) δ 101.6, 108.4, 108.6, 117.2, 124.7, 126.5, 129.9,
133.2, 135.5, 139.8, 142.2, 144.3, 147.6, 149.6, 151.9, 152.4, 154.4,
155.2. LRMS (ES+) m/z 443.3 [M + H]+. HRMS calcd for
C18H14N6O4S [M + H]
+ 443.1285, found 443.1289.
4-(6-(4-Dibenzofuryl)-9H-purin-2-ylamino)benzenesulfonamide
(75). Synthesized in accordance with general procedure A from 68
(0.15 g, 0.49 mmol). Purification by chromatography (silica; 50%
EtOAc:petrol) gave 75 as a white solid (0.10 g, 47%); mp 213-215 °C;
UV λmax (EtOH) 292, 250 nm. IR (cm
−1) 3275, 3199, 3104, 2921,
2852, 1714, 1593, 1574, 1535, 1500, 1355, 1146. 1H NMR (300 MHz,
DMSO-d6) δ 7.16 (2H, br s, SO2NH2), 7.44−7.53 (1H, dd, J = 6.9, 7.0
Hz, H-2″), 7.54−7.68 (2H, m, H-7″ and H-8″), 7.68−7.74 (1H, d, J =
8.0 Hz, H-9″), 7.69−7.79 (2H, d, J = 8.0 Hz, H-2′ and H-6′), 8.18−
8.26 (2H, d, J = 8.0 Hz, H-3′ and H-5′), 8.23−8.32 (1H, d, J = 6.9 Hz,
H-3″), 8.38 (1H, s, H-8), 8.38−8.44 (1H, d, J = 7.5 Hz, H-6″), 8.49−
8.58 (1H, d, J = 7.0 Hz, H-1″), 10.07 (1H, br s, NH), 13.22 (1H, br s,
NH). 13C NMR (125 MHz, DMSO-d6) δ 111.5, 117.3, 121.0, 121.3,
122.9, 123.1, 123.2, 123.4, 124.9, 126.4, 128.0, 130.0, 135.4, 143.0,
144.4, 152.2, 153.0, 154.4, 155.3, 155.7. LRMS (ES+) m/z 457.3 [M +
H]+. HRMS calcd for C23H16N6O3S [M + H]
+ 457.1077, found
457.1075.
6-(4-Thianthren-1-yl)-9H-purin-2-ylamino)benzenesulfonamide
(76). Synthesized following general procedure A from (69) (0.17 g,
0.49 mmol), and purified by chromatography (silica; 50% EtOAc:pe-
trol) to furnish 76 as an orange solid (81 mg, 33%); mp 170−172 °C;
UV λmax (EtOH) 339, 294, 250 nm. IR (cm
−1) 3317, 2922, 2851,
1706, 1588, 1524, 1371, 1146. 1H NMR (300 MHz, DMSO-d6) δ 7.16
(2H, s, SO2NH2), 7.21−7.28 (1H, dd, J = 7.4, 7.5 Hz, H-3″), 7.30−
7.36 (1H, dd, J = 7.5, 7.6 Hz, H-7″), 7.38−7.43 (1H, d, J = 7.5 Hz, H-
9″), 7.48−7.53 (1H, dd, J = 7.5, 7.6 Hz, H-8″), 7.58−7.63 (1H, d, J =
7.5 Hz, H-6″), 7.73 (2H, d, J = 8.5 Hz, H-2′ and H-6′), 7.77−7.80
(1H, d, J = 7.4 Hz, H-2″), 7.88−7.91 (1H, d, J = 7.5 Hz, H-4″), 8.06
(2H, d, J = 8.5 Hz, H-3′ and H-5′), 8.34 (1H, s, H-8). LRMS (ES+) m/
z 505.2 [M + H]+. HRMS calcd for C23H16N6O2S3 [M + H]
+
505.0570, found 505.0573.
7-Chloro-3-(4-methoxybenzyl)-3H-imidazo[4,5-b]pyridin-5-
amine (78). To a stirred solution of 77 (0.04 g, 0.24 mmol) in
anhydrous DMF (1 mL) was added anhydrous K2CO3 (36 mg, 0.26
mmol) and 4-methoxybenzyl chloride (34 μL, 0.25 mmol). The
reaction mixture was stirred under N2 at 65 °C for 18 h, and the
solvent was removed under reduced pressure. The residual solid was
redissolved in EtOAc (30 mL) and washed with brine (3 × 30 mL),
and the combined organic fractions were dried (Na2SO4) and the
solvent was removed under reduced pressure. Purification by
chromatography (silica; 40% EtOAc:petrol) afforded 78 as a light-
yellow solid (29 mg, 42%); Rf 0.21 (40% EtOAc:petrol); mp 105 °C;
UV λmax (EtOH) 311 nm. IR (cm
−1) 3431, 3312, 3198, 3022, 2940,
2798, 1571, 1513. 1H NMR (500 MHz, DMSO-d6) δ 3.71 (3H, s,
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OCH3), 5.22 (2H, s, CH2), 6.24 (2H, br s, NH2), 6.48 (1H, s, H-5),
6.88 (2H, d, J = 8.7 Hz, H-2″ and H-6″), 7.23 (2H, d, J = 8.8 Hz, H-3″
and H-5″), 8.07 (1H, s, H-2). 13C NMR (125 MHz, DMSO-d6) δ 45.4
(Ar-CH2-Ar), 55.1 (OCH3), 103.8 (Ar-C), 114.0 (Ar-C), 124.4 (Ar-
C), 128.7 (Ar-C), 129.2 (Ar-C), 133.9 (Ar-C), 140.5 (Ar-C), 146.6
(Ar-C), 157.4 (Ar-C), 158.7 (Ar-C). HRMS calcd for C14H14ClN4O
[M + H]+ 289.0851, found 289.0855.
7-(Cyclohexylmethoxy)-3-(4-methoxybenzyl)-3H-imidazo[4,5-b]-
pyridin-5-amine (79). Synthesized following general method C from
78 (0.172 g, 0.60 mmol). The product was isolated by chromatog-
raphy (silica; 80% EtOAc:petrol) to furnish 79 as a colorless oil (0.16
g, 0.45 mmol, 75%); Rf 0.47 (20% EtOAc:petrol); UV λmax (EtOH)
271 nm. IR (cm−1) 3311, 2954, 2899, 2163, 1672, 1598, 1516. 1H
NMR (500 MHz, DMSO-d6) δ 0.90−1.87 (11H, m, cyclohexyl), 3.71
(3H, s, OCH3), 4.00 (2H, d, J = 6.7 Hz, OCH2), 5.17 (2H, br s, NH2),
5.24 (2H, s, CH2), 5.90 (1H, s, H-5), 6.87 (2H, d, J = 8.7 Hz, H-2″
and H-6″), 7.20 (2H, d, J = 8.8 Hz, H-3″ and H-5″), 7.82 (1H, s, H-2).
13C NMR (125 MHz, DMSO-d6) δ 25.2 (CH2), 26.0 (CH2), 29.1
(CH2), 37.0 (CH), 45.0 (Ar-CH2), 55.1 (CH3), 73.3 (CH2), 87.5 (Ar-
C), 113.9 (Ar-C), 118.2 (Ar-C), 128.7 (Ar-C), 129.7 (Ar-C), 137.9
(Ar-C), 147.4 (Ar-C), 157.8 (Ar-C), 158.5 (Ar-C), 158.6 (Ar-C).
HRMS calcd for C21H27N4O2 [M + H]
+ 367.2129, found 367.2132.
7-(Cyclohexylmethoxy)-3H-imidazo[4,5-b]pyridin-5-amine (80).
A solution of 79 (0.035 g, 0.10 mmol) in TFA (1 mL) was heated
under reflux for 2 h, and the cooled solution was neutralized with
saturated aqueous NaHCO3 (25 mL). The reaction mixture was
extracted with EtOAc (3 × 30 mL), and the combined organic fraction
was dried (MgSO4) and evaporated under reduced pressure.
Purification by chromatography (silica; 10% MeOH:DCM) to furnish
80 as a white solid (16.5 mg, 70%); mp 99−102 °C; UV λmax (EtOH)
293, 244 nm. IR (cm−1) 3447, 3323, 3187, 2923, 2850, 2795, 2026,
1591, 1527. 1H NMR (500 MHz, CDCl3) δ 1.03−2.00 (11H, m,
cyclohexyl), 4.03 (2H, d, J = 6.1 Hz, OCH2), 4.37 (2H, br s, NH2),
5.91 (1H, s, H-5), 7.77 (1H, s, H-2), 9.89 (1H, br s, NH). 13C NMR
(125 MHz, CDCl3) δ 25.7, 26.4, 29.8, 37.5, 74.4, 88.1, 157.3. HRMS
calcd for C13H19N4O [M + H]
+ 247.1553, found 247.1556.
7-(Cyclohexylmethoxy)-5-iodo-3-(4-methoxybenzyl)-3H-imidazo-
[4,5-b]pyridine (81). A solution of 79 (0.112 g, 0.31 mmol) in THF (4
mL) containing diiodomethane (123 μL, 1.50 mmol), CuI (59 mg,
0.31 mmol), and isoamyl nitrite (187 μL, 0.92 mmol) was heated to
reflux for 4 h, and the dark-brown solution was filtered (Celite) and
extracted with EtOAc (2 × 20 mL). The combined organic fraction
was washed sequentially with aqueous sodium thiosulfate solution
(10%, 2 × 40 mL) and brine (40 mL) and dried (MgSO4), and the
solvent was removed in vacuo. Purification by chromatography (silica;
30% EtOAc:petrol) afforded 81 as a yellow oil (64 mg, 44%); Rf 0.19
(30% EtOAc:petrol); UV λmax (EtOH) 262 nm. IR (cm
−1) 3333, 2951,
2891, 2122, 1672, 1584, 1521. 1H NMR (500 MHz, DMSO-d6) δ
0.98−1.89 (11H, m, cyclohexyl), 3.71 (3H, s, OCH3), 4.19 (2H, d, J =
6.5 Hz, OCH2), 5.17 (2H, s, CH2), 6.90 (2H, d, J = 8.7 Hz, H-2″ and
H-6″), 7.18 (1H, s, H-5), 7.26 (2H, d, J = 8.8 Hz, H-3″ and H-5″),
8.31 (1H, s, H-2). 13C NMR (125 MHz, DMSO-d6) δ 25.1 (CH2),
25.9 (CH2), 28.9 (CH2), 37.0 (CH), 45.8 (Ar-CH2), 55.1 (CH3), 74.4
(CH2), 112.0 (Ar-C), 112.7 (Ar-C), 114.1 (Ar-C), 124.6 (Ar-C), 128.8
(Ar-C), 129.0 (Ar-C), 142.6 (Ar-C), 148.5 (Ar-C), 157.0 (Ar-C),
158.8 (Ar-C). HRMS calcd for C21H25IN3O2 [M + H]
+ 478.0986,
found 478.0980.
4-((7-(Cyclohexylmethoxy)-3-(4-methoxybenzyl)-3H-imidazo[4,5-
b]pyridin-5-yl) amino)benzenesulfonamide (82). To a solution of 81
(0.048 g, 0.10 mmol) in anhydrous MeCN (2 mL) was added
sulfanilamide (19 mg, 0.11 mmol), anhydrous K2CO3 (28 mg, 0.20
mmol), Pd2(dba)3 (2.3 mg, 0.004 mmol), and XPhos (1.9 mg, 0.004
mmol). The reaction mixture was degassed under N2 for 30 min and
stirred at 80 °C for 2 h. The cooled solution was filtered (Celite)
extracted with EtOAc (2 × 20 mL), and the combined organic extract
was washed sequentially with aqueous HCl (1 M, 20 mL), saturated
aqeuous NaHCO3 (20 mL), and brine (30 mL), and dried (Na2SO4),
and the volatiles were evaporated in vacuo. Purification by
chromatography (silica; 70% EtOAc:petrol) yielded 82 as a white
solid (23 mg, 43%); Rf 0.59 (70% EtOAc:petrol); mp 142 °C; UV λmax
(EtOH) 257 nm. IR (cm−1) 3329, 2933, 2874, 2158, 1662, 1588,
1501. 1H NMR (500 MHz, CDCl3) δ 1.00−1.97 (11H, m, cyclohexyl),
3.79 (3H, s, OCH3), 4.01 (2H, d, J = 6.1 Hz, OCH2), 4.76 (2H, br s,
NH2), 5.28 (2H, s, CH2), 6.17 (1H, s, H-5), 6.79 (1H, br s, NH), 6.88
(2H, d, J = 8.8 Hz, H-2″ and H-6″), 7.24 (2H, d, J = 8.7 Hz, H-3″ and
H-5″), 7.61 (2H, J = 8.8 Hz, H-2′ and H-6′), 7.81 (2H, J = 8.8 Hz, H-
3′ and H-5′), 8.11 (1H, s, H-2). 13C NMR (125 MHz, CDCl3) δ 25.7
(CH2), 26.4 (CH2), 29.8 (CH2), 37.6 (CH2), 46.9 (CH), 55.4 (CH2),
74.8 (OCH3), 90.7 (OCH2), 114.3 (Ar-C), 117.1 (Ar-C), 128.0 (Ar-
C), 129.1 (Ar-C), 139.7 (Ar-C), 145.5 (Ar-C), 152.1 (Ar-C). HRMS
calcd for C27H32N5O4S [M + H]
+ 522.2170, found 522.2166.
4-((7-(Cyclohexylmethoxy)-3H-imidazo[4,5-b]pyridin-5-yl)amino)
benzenesulfonamide (83). A solution of 82 (0.022 g, 0.042 mmol) in
TFA (1 mL) was heated under reflux for 2 h, and the cooled solution
was neutralized with saturated aqueous NaHCO3 (25 mL). The
reaction mixture was extracted with EtOAc (3 × 30 mL), and the
combined organic fraction was dried (MgSO4) and evaporated under
reduced pressure. The title compound was purified by preparative
TLC on silica, using 5% MeOH:DCM as eluent, to afford 83 as a
white solid (16.7 mg, 99%); Rf 0.25 (5% MeOH:DCM); mp 165−166
°C; UV λmax (EtOH) 324, 274 nm. IR (cm
−1) 3332, 2925, 2852, 2164,
1677, 1583, 1500. 1H NMR (500 MHz, MeOD-d4) δ 1.07−2.05 (11H,
m, cyclohexyl), 4.03 (2H, d, J = 6.2 Hz, OCH2), 6.33 (1H, s, H-5),
7.77 (2H, d, J = 8.9 Hz, H-2′ and H-6′), 7.92 (2H, d, J = 8.8 Hz, H-3′
and H-5′), 7.96 (1H, s, H-2). 13C NMR (125 MHz, CDCl3) δ 26.9
(CH2), 27.6 (CH2), 30.8 (CH2), 38.9 (CH), 74.9 (CH2O), 90.9 (Ar-
C), 117.9 (Ar-C), 128.2 (Ar-C). HRMS calcd for C19H24N5O3S [M +
H]+ 522.2170, found 522.2166. HPLC: >98%, XSELECT column,
retention time 5.47 min, reverse phase, H2O/MeCN/HCOOH
gradient run, 1 mL min−1.
7-(Cyclohexylmethoxy)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-
amine (86). Prepared in accordance with general procedure C from 84
(1.50 g, 8.82 mmol). Precipitation from aqueous AcOH, and repeated
washing with water gave 86 a pale-orange solid (1.52 g, 70%); mp
214−216 °C; UV λmax (EtOH) 285 nm. IR (cm−1) 3494, 3378, 2925,
2780, 2651, 2362, 2329, 2115, 2085, 2013, 1906, 1628, 1608, 1578,
1488. 1H NMR (500 MHz, DMSO-d6) δ 1.03−1.89 (11H, m,
cyclohexyl), 4.30 (2H, d, J = 6.5 Hz, OCH2), 6.91 (2H, br s, NH2),
15.28 (1H, br s, NH). 13C NMR (125 MHz, DMSO-d6) δ 25.1 (CH2),
25.9 (CH2), 29.1 (CH2), 36.6 (CH), 71.2 (CH2), 162.2 (Ar-C).
HRMS calcd for C11H17N6O [M + H]
+ 249.1458, found 249.1461.
4-(Cyclohexylmethoxy)-1H-pyrazolo[3,4-d]pyrimidin-6-amine
(87). Prepared according to the general procedure C from 85 (0.125 g,
0.74 mmol). Purification by chromatography (silica; 10%
MeOH:DCM) gave 87 as an off white crystalline solid (68 mg,
37%); Rf 0.70 (10% MeOH:DCM), mp 193−195 °C; UV λmax
(EtOH) 275 nm. IR (cm−1) 3498, 3353, 3232, 3121, 2960, 2921,
2851, 2750, 2667, 2158, 2038, 1902, 1794, 1633, 1578, 1497, 1469,
1441. 1H NMR (500 MHz, DMSO-d6) δ 0.98−1.82 (11H, m,
cyclohexyl), 4.21 (2H, d, J = 6.5 Hz, OCH2), 6.55 (2H, br s, NH2),
7.77 (1H, s, CH), 12.78 (1H, br s, NH). 13C NMR (125 MHz,
DMSO-d6) δ 25.2 (CH2), 26.0 (CH2), 29.1 (CH2), 36.7 (CH), 70.5
(CH2), 95.4 (Ar-C), 131.6 (Ar-C), 158.9 (Ar-C), 162.0 (Ar-C), 163.4
(Ar-C). HRMS calcd for C12H18N5O [M + H]
+ 248.1506, found
248.1508.
5-Chloro-7-(cyclohexylmethoxy)-3H-[1,2,3]triazolo[4,5-d]-
pyrimidine (88). To a solution of LiCl (34 mg, 0.80 mmol) in DMA
(0.5 mL) at 0 °C was added 86 (0.05 g, 0.20 mmol), followed by
isoamyl nitrite (61 μL, 0.30 mmol) and SOCl2 (16 μL, 0.22 mmol).
The reaction mixture was stirred for 1 h and allowed to warm to
ambient temperature over 18 h. After addition of saturated aqueous
NaHCO3 (15 mL), the reaction mixture was extracted with EtOAc (3
× 15 mL), and the combined organic layers were washed with brine (2
× 30 mL) and dried (Na2SO4). Evaporation of the solvent under
reduced pressure furnished 88 as a brown oil (54 mg, > 99%), which
was used directly without further purification.
6-Chloro-4-(cyclohexylmethoxy)-1H-pyrazolo[3,4-d]pyrimidine
(89). To a solution of LiCl (69 mg,1.62 mmol) in DMA (1 mL) at 0
°C was added 87 (0.100 g, 0.40 mmol), followed by isoamyl nitrite
(123 μL, 0.61 mmol) and SOCl2 (32 μL, 0.45 mmol). The reaction
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mixture was stirred at room temperature for 18 h, cooled, and EtOAc
(45 mL) was added. The resultant solution was washed sequentially
with aqueous saturated NaHCO3 solution (45 mL) and brine (2 × 45
mL), dried (Na2SO4), and the volatiles were evaporated under reduced
pressure. The product was purified by chromatography (silica; 5%
MeOH:DCM) to give 89 as a yellow solid (65 mg, 60%); Rf 0.32 (5%
MeOH:DCM), mp 152−153 °C; UV λmax (EtOH) 252 nm. IR (cm−1)
3148, 2922, 2851, 1677, 1579, 1443. 1H NMR (500 MHz, CDCl3) δ
0.96−1.95 (11H, m, cyclohexyl), 4.39 (2H, d, J = 6.0 Hz, OCH2), 8.09
(1H, s, CH), 11.19 (1H, br s, NH). 13C NMR (125 MHz, DMSO-d6)
δ 25.2 (CH2), 26.0 (CH2), 29.1 (CH2), 36.7 (CH), 70.5 (CH2O), 95.4
(Ar-C), 131.6 (C1-H), 158.9 (Ar-C), 162.0 (Ar-C), 163.4 (Ar-C).
HRMS calcd for C12H16ClN4O [M + H]
+ 267.1007, found 267.1012.
4-((7-(Cyclohexylmethoxy)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-
yl)amino) benzenesulfonamide (90). The title compound was
prepared following general procedure A from 88 (0.054 g, 0.20
mmol) and isolated by chromatography (silica; 30% EtOAc:petrol) to
give the title compound 90 as a white solid (28 mg, 35%); Rf 0.18
(70% EtOAc:petrol); mp 217−219 °C; UV λmax (EtOH) 310 nm. IR
(cm−1) 3254, 3121, 2924, 2851, 2363, 2342, 2199, 2140, 1992, 19118,
1700, 1582, 1534, 1492, 1447. 1H NMR (500 MHz, DMSO-d6) δ
1.04−1.92 (11H, m, cyclohexyl), 4.36 (2H, d, J = 6.8 Hz, OCH2), 7.18
(2H, br s, SO2NH2), 7.72 (2H, d, J = 8.8 Hz, H-2′ and H-6′), 7.99
(2H, d, J = 9.0 Hz, H-3′ and H-5′), 9.92 (1H, br s, NH) 13.34 (1H, br
s, NH). 13C NMR (125 MHz, DMSO-d6) δ 25.1 (CH2), 29.1 (CH2),
35.9 (CH), 118.0 (Ar-C), 126.4 (Ar-C). HRMS calcd for
C17H22N7O3S [M + H]
+ 404.1499, found 404.1500. HPLC: >99.5%,
XTerra column, retention time 11.64 min, reverse phase, H2O/
MeCN/HCOOH gradient run, 1 mL min−1.
4-((4-(Cyclohexylmethoxy)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-
amino)benzenesulfonamide (91). The title compound was prepared
by general procedure A from 89 (0.042 g, 0.18 mmol).
Chromatography (silica; 70% EtOAc:petrol) afforded 91 as a white
solid (20 mg, 28%); Rf 0.21 (70% EtOAc:petrol), mp 268−269 °C;
UV λmax (EtOH) 304 nm. IR (cm
−1) 3367, 3333, 3269, 2922, 2853,
2162, 2012, 1691, 1658, 1624, 1583, 1551, 1524. 1H NMR (500 MHz,
DMSO-d6) δ 1.04−1.92 (11H, m, cyclohexyl), 4.36 (2H, d, J = 6.8 Hz,
OCH2), 7.18 (2H, br s, SO2NH2), 7.72 (2H, d, J = 8.8 Hz, H-2′ and
H-6′), 7.98 (1H, br s, CH), 7.99 (2H, d, J = 9.0 Hz, H-3′ and H-5′),
9.92 (1H, br s, NH) 13.34 (1H, br s, NH). 13C NMR (125 MHz,
DMSO-d6) δ 25.4 (CH2), 26.5 (CH2), 29.5 (CH2), 37.1 (CH), 71.5
(CH2) 118.6 (Ar-C), 136.6 (Ar-C), 144.0 (Ar-C). HRMS calcd for
C18H23N6O3S [M + H]
+ 403.1547, found 403.1547. HPLC: >98.5%,
XTerra column, retention time 11.92 min, reverse phase, H2O/
MeCN/HCOOH gradient run, 1 mL min−1.
4-(Cyclohexylmethoxy)-7H-pyrrolo[2,3-d]pyrimidin-2-amine (93).
Prepared in accordance with general method C from 92 (0.15 g, 0.89
mmol), with heating under microwave irradiation (170 °C, 5 h). The
product was isolated by chromatography (silica; 10% MeOH:DCM)
to yield 93 as a white crystalline solid (37 mg, 17%); Rf 0.55 (10%
MeOH:DCM); mp 216.3-217.3 °C; UV λmax (EtOH) 221 nm. IR
(cm−1) 3494, 3362, 3117, 2922, 2851, 2164, 2045, 1968, 1617, 1585,
1499, 1478. 1H NMR (500 MHz, DMSO-d6) δ 0.98−1.83 (11H, m,
cyclohexyl), 4.15 (2H, d, J = 6.5, OCH2), 5.91 (2H, br s, NH2), 6.17
(1H, dd, J = 1.9 and 3.5, CH), 6.79 (1H, dd, J = 2.2 and 3.5, HNCH),
10.97 (1H, br s, NH). 13C NMR (125 MHz, DMSO-d6) δ 25.2 (CH2),
26.0 (CH2), 29.3 (CH2), 36.8 (CH), 69.9 (CH2O), 96.9 (C
1-H), 97.9
(Ar-C), 119.1 (C2-H), 155.0 (Ar-C), 159.3 (Ar-C), 162.7 (Ar-C).
HRMS calcd for C13H19N4O [M + H]
+ 247.1553, found 247.1556.
4-Chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]-
pyrimidin-2-amine (94). NaH (60% in mineral oil, 26 mg, 0.65
mmol) was added dropwise to a solution of 92 (0.10 g, 0.59 mmol) in
anhydrous MeCN (3 mL) at −30 °C, and the reaction mixture was
stirred for 45 min. 2-(Trimethylsilyl)ethoxymethyl chloride (90%, 122
μL, 0.62 mmol) was added dropwise, and the reaction mixture was
stirred for a further 3 h at room temperature. After cooling and
addition of water (20 mL), the resultant solution was extracted with
EtOAc (20 mL), and the combined organic fractions were washed
with brine (3 × 20 mL), dried (Na2SO4), and the solvent was removed
in vacuo. Purification by chromatography (silica; 15% EtOAc:petrol)
gave 94 as a yellow solid (130 mg, 74%); Rf 0.41 (15% EtOAc:petrol);
mp 63−64 °C; UV λmax (EtOH) 317, 234 nm. IR (cm−1) 3423, 3318,
3212, 3096, 2952, 1631, 1608, 1546, 1493. 1H NMR (500 MHz,
CDCl3) δ −0.04 (9H, s, (CH3)3), 0.91 (2H, t, J = 8.0 Hz,
OCH2CH2Si), 3.81 (2H, t, J = 8.3 Hz, OCH2CH2Si), 4.96 (2H, br
s, NH2), 5.44 (2H, s, CH2), 6.43 (1H, d, J = 3.7 Hz, CH), 6.99 (1H, d,
J = 3.7 Hz, NCH). 13C NMR (125 MHz, DMSO-d6) δ 0.0 (Si(CH3)3),
19.2 (CH2CH2Si), 67.7 (OCH2CH2), 74.3 (NCH2O), 102.2 (C
5H),
112.2 (Ar-C), 127.0 (C6H), 154.2 (Ar-C), 155.6 (Ar-C), 160.2 (Ar-C).
HRMS calcd for C12H20ClN4OSi [M + H]
+ 299.1089, found 299.1090.
4-(Cyclohexylmethoxy)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-
pyrrolo[2,3-d]pyrimidin-2-amine (95). Synthesized following general
procedure C from 94 (0.30 g, 1.01 mmol), except using THF as
solvent. The title compound was isolated by chromatography (silica;
15% EtOAc:petrol) to furnish 95 as a yellow solid (296 mg, 78%); Rf
0.17 (15% EtOAc:petrol); mp 88−90 °C; UV λmax (EtOH) 286, 260,
223 nm. IR (cm−1) 3346, 3222, 2926, 2852, 1647, 1602. 1H NMR
(500 MHz, CDCl3) δ −0.05 (9H, s, (CH3)3), 0.91 (2H, t, J = 8.3 Hz,
OCH2CH2Si), 1.01−1.91 (11H, m cyclohexyl), 3.51 (2H, t, J = 8.3 Hz,
OCH2CH2Si), 4.21 (2H, d, J = 6.5 Hz, OCH2), 4.68 (2H, br s, NH2),
5.41 (2H, s, CH2), 6.40 (1H, d, J = 3.7 Hz, CH), 6.82 (1H, d, J = 3.7
Hz, NCH). 13C NMR (125 MHz, DMSO-d6) δ 0.0 (Si(CH3)3), 19.2
(CH2CH2Si), 27.2 (CH2), 28.0 (CH2), 31.3 (CH2), 38.8 (CH), 67.4
(OCH2CH2), 72.6 (CH2), 74.1 (NCH2O), 101.2 (C
5H), 123.6 (C6H),
160.6 (Ar-C), 165.4 (Ar-C). HRMS calcd for C19H33N4O2Si [M + H]
+
377.2367, found 377.2367.
2-Chloro-4-(cyclohexylmethoxy)-7-((2-(trimethylsilyl)ethoxy)-
methyl)-7H-pyrrolo[2,3-d]pyrimidine (96). To a solution of LiCl in
THF (0.5 M, 2.13 mL, 1.1 mmol) was added 95 (0.10 g, 0.27 mmol),
and the reaction mixture was cooled to 0 °C. Isoamyl nitrite (81 μL,
0.40 mmol) and SOCl2 (21.3 μL, 0.29 mmol) were added, and the
solution was stirred at room temperature for 5 h. The reaction mixture
was added to a solution of aqueous NH4Cl (2 M, 30 mL), extracted
with EtOAc (2 × 30 mL), and the combined organic layers were
washed with water (3 × 30 mL), dried (Na2SO4), and evaporated in
vacuo. Purification by chromatography (silica; 15% EtOAc:petrol)
gave 96 as a clear oil (60 mg, 56%); Rf 0.45 (15% EtOAc:petrol); UV
λmax (EtOH) 270 nm. IR (cm
−1) 2924, 2852, 1750, 1661, 1588, 1558,
1506. 1H NMR (500 MHz, DMSO-d6) δ −0.09 (9H, s, (CH3)3), 0.82
(2H, t, J = 8.1 Hz, OCH2CH2Si), 0.95−1.89 (11H, m cyclohexyl), 3.50
(2H, t, J = 8.1 Hz, OCH2CH2Si), 4.28 (2H, d, J = 6.0 Hz, OCH2), 5.52
(2H, s, CH2), 6.61 (1H, d, J = 3.6 Hz, CH), 7.55 (1H, d, J = 3.5 Hz,
NCH). 13C NMR (125 MHz, DMSO-d6) δ 0.0 (Si(CH3)3), 18.5
(CH2CH2Si), 26.6 (CH2), 30.5 (CH2) 31.8 (CH2), 38.8 (CH), 67.1
(OCH2CH2), 73.3 (CH2), 74.2 (NCH2O), 100.4 (C
5H), 126.4 (C6H),
129.7 (Ar-C). HRMS calcd for C19H31ClN3O2Si [M + H]
+ 396.1869,
found 396.1872.
4-((4-(Cyclohexylmethoxy)-7-((2-(trimethylsilyl)ethoxy)methyl)-
7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)benzenesulfonamide (97).
To a degassed solution of 96 (0.050 g, 0.13 mmol) in MeCN (2
mL) was added sulfanilamide (24 mg, 0.14 mmol), anhydrous K2CO3
(35 mg, 0.25 mmol), Pd2(dba)3 (3 mg, 5.0 × 10
−3 mmol), and XPhos
(2.4 mg, 5.0 × 10−3 mmol), and the reaction mixture was stirred under
N2 at 80 °C for 2 h. The cooled mixture was filtered (Celite), diluted
with EtOAc (20 mL), and washed sequentially with aqueous HCl
solution (1 M, 20 mL), saturated aqueous NaHCO3 solution (20 mL),
and brine (30 mL). After drying (Na2SO4), volatiles were removed
under reduced pressure and the product was isolated by chromatog-
raphy (silica; 50% EtOAc:petrol) to give 97 as a yellow oil (33 mg,
49%); Rf 0.63 (50% EtOAc:petrol); UV λmax (EtOH) 269 nm. IR
(cm−1) 3644, 3342, 2924, 2853, 1586, 1528, 1488. 1H NMR (500
MHz,CDCl3) δ −0.08 (9H, s, Si(CH3)3), 0.88−0.95 (2H, t, J = 8.36
Hz, OCH2CH2Si) 1.04−1.93 (11H, m, cyclohexyl), 3.56 (2H, t, J = 3.4
Hz, OCH2CH2Si) 4.29 (2H, d, J = 6.5 Hz, OCH2), 4.72 (2H, br s,
NH2), 5.52 (2H, s, CH2), 6.49 (1H, d, J = 3.5 Hz, CH), 6.96 (1H, d, J
= 3.6 Hz, NCH), 7.20 (1H, br s, NH), 7.87 (4H, ap s, H-2′, H-3′, H-5′
and H-6′). 13C NMR (125 MHz, CDCl3) δ 0.0 (SiCH3), 15.6
(CH2Si), 27.2 (CH2), 27.9 (CH2), 31.3 (CH2), 38.8 (CH), 67.8
(CH2), 73.2 (CH2), 74.5 (CH2), 101.5 (Ar-C), 101.9 (Ar-C), 118.8
(Ar-C), 125.0 (Ar-C), 129.3 (Ar-C), 146.2 (Ar-C). HRMS calcd for
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C25H38N5O4SSi [M + H]
+ 532.2408, found 532.2406. Note: Not all
carbons are visible.
4-((4-(Cyclohexylmethoxy)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)-
amino)benzenesulfonamide (98). A solution of 97 (0.040 g, 7.5 ×
10−2 mmol) in TFA (1.5 mL) was heated under reflux for 10 min, and
the cooled solution was neutralized with saturated aqueous NaHCO3
solution. The aqueous solution was extracted with EtOAc (2 × 30
mL), and the solvent was evaporated under reduced pressure. The
residual yellow solid was redissolved in MeCN:H2O (1:1, 8 mL), the
pH of the solution was adjusted to 10 with dilute aqueous ammonia
(28%), and the solution was stirred for 1 h at room temperature and
evaporated in vacuo. Isolation by chromatography (silica; 70%
EtOAc:petrol) to give 98 as a white solid (12 mg, 40%); Rf 0.39
(70% EtOAc:petrol); mp 251.2−252.0 °C; UV λmax (EtOH) 312 nm.
IR (cm−1) 3374, 3322, 2058, 2924, 2856, 2012, 1615, 1595, 1579. 1H
NMR (500 MHz, DMSO-d6) δ 1.07−1.95 (11H, m, cyclohexyl), 4.31
(2H, d, J = 6.3 Hz, OCH2), 6.34 (1H, dd, J = 2.1 and 2.1 Hz, CH),
7.05 (1H, dd, J = 2.2 and 2.2 Hz, HNCH), 7.13 (2H, br s, SO2NH2),
7.68 (2H, d, J = 8.9 Hz, H-2′ and H-6′) 7.99 (2H, d, J = 8.8 Hz, H-3′
and H-5′), 9.57 (1H, br s, NH), 11.54 (1H, br s, NH). 13C NMR (125
MHz, DMSO-d6) δ 25.2 (CH2), 26.0 (CH2), 29.3 (CH2), 36.8 (CH),
70.6 (CH2), 98.2 (C
5H), 116.9 (Ar-C), 126.4 (C6H), 134.9 (Ar-C),
144.6 (Ar-C), 146.4 (Ar-C), 153.6 (Ar-C), 154.4 (Ar-C), 162.4 (Ar-
C). HRMS calcd for C19H24N5O3S [M + H]
+ 402.1594, found
402.1596. HPLC: >99.5%, XSELECT column, retention time 8.45
min, reverse phase, H2O/MeCN/HCOOH gradient run, 1 mL min
−1.
7-Chloro-5-cyclohexylmethoxyimidazo[1,2-a]pyrimidine (100).
Synthesized in accordance with general procedure C from 99 (1.0 g,
5.4 mmol). The product was purified by precipitation with glacial
acetic acid, and repeated washing with water, to afford 100 as a pale-
orange powder (1.16 g, 81%); Rf 0.23 (60% EtOAc:petrol).
1H NMR
(300 MHz, DMSO-d6) δ 1.05−1.95 (11H, m, cyclohexyl), 4.30 (2H,
d, J = 6.1 Hz, OCH2), 6.63 (1H, s, H-6), 7.63 (2H, d, J = 1.2 Hz, H-3),
7.81 (2H, d, J = 1.3 Hz, H-2). 13C NMR (75 MHz, DMSO-d6) δ 25.4,
26.2, 29.0, 36.9, 76.3, 88.8, 107.6, 134.2, 148.1, 152.1, 155.6. LRMS
(ES+) m/z 266.0 [M + H]+.
5-Cyclohexylmethoxy-7-anilinoimidazo[1,2-a]pyrimidine (101).
The title compound was synthesized according to general procedure
A from 100 (0.075 mg, 0.28 mmol). Purification by chromatography
(silica; EtOAc), followed by crystallization from MeOH, gave 101 (31
mg, 34%); Rf 0.11 (100% EtOAc); mp 252−253 °C; UV λmax (EtOH)
305, 257, 212 nm. IR (cm−1) 3153, 2926, 2847, 2161, 1627, 1595,
1568, 1531, 1489, 1291, 1259, 1122. 1H NMR (300 MHz, DMSO-d6)
δ 1.05−1.85 (11H, m, cyclohexyl), 4.35 (2H, d, J = 6.2 Hz, OCH2),
5.98 (1H, s, H-6), 6.99 (1H, t, J = 7.3 Hz, PhH), 7.26 (1H, d, J = 1.6
Hz, H-3), 7.33 (2H, dd, J = 7.6, 8.2 Hz, 2 × PhH), 7.44 (1H, d, J = 1.6
Hz, H-2), 7.83 (2H, d, J = 7.7 Hz, 2 × PhH), 9.45 (1H, s, NH). LRMS
(ES+) m/z 323.0 [M + H]+. Anal. Found: C, 70.41; H, 6.59; N, 17.40.
C19H22N4O requires C, 70.78; H, 6.88; N, 17.38%.
5-Cyclohexylmethoxy-7-(4′-sulfamoylanilino)imidazo[1,2-a]-
pyrimidine (102). Prepared in accordance with general procedure A
from 100 (0.25 g, 0.94 mmol), and purified by chromatography (silica;
5% MeOH:EtOAc) to give 102 as a colorless solid (28 mg, 7%); Rf
0.47 (10% MeOH:EtOAc); mp 228−229 °C. IR (cm−1) 3348, 3292,
2926, 2847, 1653, 1617, 1591, 1536, 1429, 1310, 1155. UV λmax
(EtOH) 315, 266, 216 nm. 1H NMR (300 MHz, DMSO-d6) δ 1.15−
1.90 (11H, m, cyclohexyl), 4.16 (2H, d, J = 6.1 Hz, OCH2), 6.03 (1H,
s, H-6), 7.24 (2H, s, SO2NH2), 7.32 (1H, d, J = 1.6 Hz, H-3), 7.51
(1H, d, J = 1.6 Hz, H-2), 7.78 (2H, d, J = 8.9 Hz, H-2′ and H-6′), 7.99
(2H, d, J = 8.9 Hz, H-3′ and H-5′), 9.85 (1H, s, NH). 13C NMR (75
MHz, DMSO-d6) δ 25.45, 26.19, 29.16, 36.85, 75.00, 78.91, 105.83,
118.42, 127.05, 131.95, 137.03, 144.01, 154.73, 155.68. LRMS (ES+)
m/z 402.0 [M + H]+; Anal. Found: C, 57.06; H, 5.53; N, 17.09.
C19H23N5O3S requires: C, 56.84; H, 5.77; N, 17.44%.
Protein Kinase Assays. Human CDK1/B was purchased from
New England Biolabs or prepared as described,46 CDK2/A2 was
prepared as described,46 CDK4/D was provided by AstraZeneca, and
CDK7/H and CDK9/T were purchased from Upstate. IC50 values for
CDK1/B, CDK2/A, and CDK4/D were determined as described.23
IC50 values for CDK7/H and CDK9/H were determined according to
the supplier’s instructions (Upstate). CDK1/B, CDK2/A, and CDK4/
D were assayed at an ATP concentration of 12.5 μM, CDK7/H and
CDK9/T at an ATP concentration of 100 μM. Published Km(ATP)
values for CDK1-cyclin B, CDK2-cyclin A, CDK4-cyclin D2, CDK7-
cyclin H-MAT, and CDK9-cyclin T are 0.8, 0.58, 3.8, 4.1, and 0.7 μM,
respectively (www.proqinase.com).
Growth Inhibition Assays. The ability of selected compounds to
inhibit cell growth was assessed in a panel of human cancer cell lines
using an SRB assay.45 Briefly, cells in 96-well plates were exposed to
inhibitor (0.1−30 μM, three replicates per drug concentration) or
0.5% (v/v) DMSO (for compound 73 treatments) or 0.1% (v/v)
DMSO (for all other inhibitors) for 120 h, stained with sulforhod-
amine B and the absorbance at 570 nm measured (SpectraMax250;
Molecular Devices, Wokingham, UK). At least three independent
experiments were performed. Growth inhibitory GI50 values were
calculated using GraphPad Prism software (GraphPad Software, Inc.,
San Diego, CA).
Crystallization and Structure Determination. Crystals of
CDK2-cyclin A bound to 73 and CDK1-cyclin B-CKS2 bound to 3
were grown as previously described.46 Briefly, the inhibitors were
added in 2-fold molar excess (which was also a 10-fold higher
concentration than the inhibitor IC50) to a low concentration solution
of the appropriate protein complex and then the samples were
concentrated to 10−12 mg mL−1 for crystallization. CDK2-cyclin A−
73 crystals were grown from a well solution containing 0.6−0.8 M
KCl, 0.9−1.2 M (NH4)2SO4, and 100 mM HEPES (pH 7.0). CDK1-
cyclin B-CKS2 was cocrystallized with 3 from a screen covering the
conditions 0.1 M MES/imidazole buffer (pH 6.7), 6.5% MPD, 5%
PEG4K, 10% PEG1K. Before data collection, crystals were
cryoprotected by brief immersion in either 8 M sodium formate
(CDK2-cyclin A) or 25% ethylene glycol (CDK1-cyclin B-CKS2).
Data processing was carried out using XDS, MOSFLM,
POINTLESS/AIMLESS,52 and other programs of the CCP4 suite,53
run through the CCP4i2 GUI.54 The structures of the different
complexes were solved by molecular replacement using Phaser,55 and
search models drawn from PDB entries 1QMZ (cyclin A-bound
CDK2) and 4Y72 (CDK1-cyclin B-CKS2). Models of 73 and 3 and
ligand restraints were generated using ACEDRG within the CCP4i2
suite,54 and built into the electron density using Coot.56 Structures
were refined using REFMAC,57 interspersed with manual rebuilding in
Coot, including TLS refinement.
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